

B-1/1018, VASANT KUNJ, NEW DELHI - 110 070 TELEPHONE: 011-41082626

EMAIL : rohit_mehra@rnaca.in rnaca1@gmail.com

Independent Auditors' Examination Report on the Restated Consolidated Statement of Assets and Liabilities as at March 31, 2023, March 31, 2022 and March 31, 2021, Restated Consolidated Statement of Profit and Loss (including other comprehensive income), Restated Consolidated Statement of Cash Flows and changes in equity for the year ended March 31, 2023, years ended March 31, 2022 and March 31, 2021, along with the Restated Statement of significant accounting policies and other explanatory information of Yatharth Hospital & Trauma Care Services Limited (collectively, the "Restated Consolidated Financial Information").

To the Board of Directors
Yatharth Hospital & Trauma Care Services Limited
JA 108 DLF Tower A, Jasola District Centre,
South Delhi, Delhi – 110025, India.

Dear Sirs/Madams,

- 1. We have examined the accompanying Restated Consolidated Financial Information of Yatharth Hospital & Trauma Care Services Limited (the "Company" or the "Holding Company" or the "Issuer") and its subsidiaries (the Company and its subsidiaries together referred to as the "Group") which comprises of Restated Consolidated Statement of Assets and Liabilities as at March 31, 2023, March 31, 2022 and March 31, 2021, the Restated Consolidated Statement of Profit and Loss (including other comprehensive income), the Restated Consolidated Statement of Changes in Equity and the Restated Consolidated Statement of Cash Flows for the year ended March 31, 2023, March 31, 2022 and March 31, 2021 and the Significant Accounting Policies and other explanatory Information (collectively referred to as the "Restated Consolidated Financial Information"), annexed to this report for the purpose of inclusion in the Red Herring Prospectus ("RHP") and the Prospectus prepared by the Company in connection with its proposed initial public offer of its equity shares of face value of Rs. 10 each (the "Offer"). The Restated Consolidated Financial Information, as approved by the Board of Directors of the Company at their meeting held on 05th July 2023, have been prepared by the Company in accordance with the requirements of:
 - a) Section 26 of Part 1 of Chapter III of the Companies Act, 2013 (the "Act");
 - b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "SEBI ICDR Regulations"); and
 - c) The Guidance Note on Reports in Company Prospectus (Revised 2019) (as amended) issued by the Institute of Chartered Accountants of India ("ICAI"), as amended from time to time ("the Guidance Note").
- 2. The Company's Board of Directors are responsible for the preparation of Restated Consolidated Financial Information for the purpose of inclusion in the RHP and the Prospectus to be filed with the Registrar of Companies, National Capital Territory of Delhi and Haryana ("RoC"), the Securities and Exchange Board of India ("SEBI"), the National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE",) where the equity shares of the Company are proposed to be listed ("Stock Exchanges") in connection with the Offer. The Restated Consolidated Financial Information have been prepared by the management of the Group in accordance with the basis of preparation stated in Note of Annexure to the Restated Consolidated Financial Information.

The respective board of directors of the companies included in the Group are responsible for designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Consolidated Financial Information. The respective Board of Directors are also responsible for

R

identifying and ensuring that the Group complies with the Act, the SEBI ICDR Regulations and the Guidance Note.

- 3. We have examined the Restated Consolidated Financial Information taking into consideration:
 - a. the terms of reference and terms of our engagement agreed upon with Company vide our engagement letter dated 04.03.2022, in connection with the Offer;
 - b. the Guidance Note, which also requires that we comply with ethical requirements of the Code of Ethics issued by ICAI;
 - c. the concepts of test checks and materiality to obtain reasonable assurance based on the verification of evidence supporting the Restated Consolidated Financial Statements; and
 - d. The requirements of Section 26 of the Act and applicable provisions of the SEBI ICDR Regulations.

Our work was performed solely to assist you in meeting your responsibilities in relation to compliance with the Act, Guidance Note and the SEBI ICDR Regulations in connection with the Offer.

- These Restated Consolidated Financial Information have been compiled by the Management of the Company from:
 - a. Audited Consolidated Ind AS Financial Statements of the Group as at and for the year ended March 31, 2023 prepared by the Management in accordance with the Ind AS, as prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as amended, and other accounting principles generally accepted in India, which has been approved by the Board of Directors at their meeting held on June 17th,2023;
 - b. Audited Consolidated Ind AS Financial Statements of the Group as at and for the year ended March 31, 2022 prepared by the Management in accordance with the Ind AS, as prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as amended, and other accounting principles generally accepted in India, which has been approved by the Board of Directors at their meeting held on August 04th,2022 and
 - c. Audited Special Purpose Consolidated Ind AS Financial Statements of the Group as at and for the year ended March 31, 2021 prepared by the Management in accordance with the Ind AS, as prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as amended, and other accounting principles generally accepted in India, which has been approved by the Board of Directors at their meeting held on March 25th, 2022.
- 5. For the purpose of our examination, we have relied on:
 - Auditor's reports issued by us dated June 17th,2023 on the Special Purpose Consolidated Ind AS Financial Statements of the Group for the year March 31st,2023 as referred in Para 4 (a) above;
 - b. Auditor's report issued by us dated August 04, 2022 on the Consolidated Ind AS Financial Statements of the Group as at and for the year ended March 31, 2022 as referred in Para 4 (b) above;
 - c. Auditor's report issued by us dated March 25, 2022 on the Special Purpose Consolidated Ind AS Financial Statements of the Group as at and for the year ended March 31, 2021, as referred in Para 4 (c) above;
- 6. The audit reports on Consolidated Ind AS Financial Statements of the Group for the years ended March 31, 2023 and March 31, 2022 and on the Special Purpose Consolidated Ind AS Financial Statements of the Group Defor the year ended March 31, 2021 referred to in paragraph 5 above include the financial statements / financial

information of three subsidiaries whose financial statements/ financial information reflect total assets, total revenues and net cash inflows, for the relevant years is tabulated below, which have been audited by other auditors and whose report have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and our report in terms of sub-sections (3) and (11) of Section 143 of the Act in so far as it relates to the aforesaid subsidiaries is based solely on such audited financial statements / financial information as provided by other auditors.

Rs. In Millions

| Particulars | As at 31st March 2023 | As at 31st March 2022 | As at 31st March 2021 |
|------------------|-----------------------|--------------------------|-----------------------|
| Total Assets | 2,196.78 | 1,979.50 | 1,366.56 |
| Total Revenues | 1,497.75 | 1,023.47 | 795.42 |
| Total Cash Flows | 150.61 | 58.26 | 40.41 |

- 7. Based on our examination and according to the information and explanations given to us, we report that Restated Consolidated Financial Information:
 - a. have been prepared after incorporating adjustments for the changes in accounting policies, material errors, and regrouping / reclassifications retrospectively in the financial years as at and for the years ended March 31, 2023, March 31, 2022 and March 31, 2021 to reflect the same accounting treatment as per the accounting policies and grouping/ classifications;
 - b. does not contain any qualifications requiring adjustments; and
 - c. have been prepared in accordance with the Act, ICDR Regulations and the Guidance Note.
- 8. This report should not in any way be construed as a reissuance or re-dating of any of the previous auditor's reports issued by us or by the Previous Auditor, nor should this report be construed as a new opinion on any of the financial statements referred to herein.
- 9. The Restated Consolidated Financial Information do not reflect the effects of events that occurred subsequent to the respective dates of the report on the audited financial statements, as mentioned in paragraph 5 above.
- 10. We have no responsibility to update our report for events and circumstances occurring after the date of this report.
- 11. Our report is intended solely for use of the Board of Directors for inclusion in the RHP and the Prospectus to be filed with the RoC, and thereafter with SEBI and Stock Exchanges in connection with the proposed Offer. Our report should not be used, referred to, or distributed for any other purpose without prior consent in writing. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For R. Nagpal Associates Chartered Accountants

ICAI Firm Reg. No. 002626N

Rohit Mehra)

Partner

Membership No:093910

UDIN: 23093910BGUFXH6948

Place: Noida Date:05/07/2023

Annexure I

Restated Consolidated Statement of Assets & Liabilities

| | | Particulars | Note No. | As at March 31, 2023 | As at March 31, 2022 | As at March 31 2021 |
|----|-------|--------------------------------------------------------------------------------------------|----------|----------------------|-----------------------------------------|----------------------|
| | | ASSETS | | | 110 40 1141 01 01, 2022 | As at March 51, 2021 |
| I | | Non-current assets | | | | |
| | (a) | Property, Plant and Equipment | 2 | 2,553.09 | 2,577.81 | 2,428.37 |
| | (b) | Intangible Assets | 3 | 2,333,07 | 0.07 | 2,428.37 |
| | (c) | Capital work in progress | | | 0.07 | - |
| | (d) | Right-of-use of assets | 30 | 35.12 | 56.12 | 75.63 |
| | (e) | Goodwill | 46 | 397.01 | 397.01 | 4.12 |
| | (f) | Financial Assets | | 557.01 | 377.01 | 4.12 |
| | | (i) Other Financial Assets | 4 | 19.56 | 22.25 | 15.94 |
| | | Deferred Tax Assets (Net) | 16 | 82.79 | 54.53 | 13.74 |
| | (h) | Other Non Current Assets | 5 | 9.41 | 58.45 | 70.44 |
| | | Total non-current assets | | 3,096.98 | 3,166.23 | 2,594.50 |
| II | | Current assets | | 10 | | |
| ** | (a) | Inventories | | | | |
| | | Financial Assets | 6 | 60.70 | 51.95 | 33.90 |
| | (5) | (i) Trade receivables | _ | | | |
| | | (ii)Cash and cash equivalents | 7 | 1,076.44 | 855.38 | 367.65 |
| | | (iii) Bank Balance other than (ii) above | 8 | 374.32 | 117.07 | 50.00 |
| | (c) | Current Tax assets (Net) | 9 | 10.11 | 3.74 | 1.52 |
| | | Other Current assets | | 111.78 | 30.23 | 18.06 |
| | (4) | Total current assets | 11 | 129.31 | 35.63 | 22.09 |
| | | Total Assets | | 1,762.67 4,859.66 | 1,094.00 4,260.23 | 493.21 |
| | | EQUITY AND LIABILITIES | | 4,837.00 | 4,200.23 | 3,087.71 |
| I | | Equity | | | | |
| | (a) | Equity Share Capital | 12 | 655.17 | 655 17 | 1/2 50 |
| | 00000 | Other Equity | 13 | 1,174.47 | 655.17 513.68 | 163.79 |
| | | Equity attributable to the owners of the company | 15 | 1,829.64 | 1,168.85 | 560.76 724.55 |
| | | Non-controlling interest | | 1,025,04 | 1,100.03 | 82.28 |
| | | Total Equity | | 1,829.64 | 1,168.85 | 806.83 |
| I | | Non-accessed Balding | | | *************************************** | |
| | | Non-current liabilities Financial liabilities | | | | |
| | | (i) Borrowings | 2.7 | | | |
| | | (i) Lease Liabilities | 14 | 2,005.94 | 2,073.82 | 1,637.18 |
| | | | 30 | 15.91 | 36.74 | 54.76 |
| | | Provisions | 15 | 12.99 | 9.78 | 0.41 |
| | (c) | Deferred tax liabilities (Net) | 16 | | 12 | 38.52 |
| | | Total non-current liabilities | | 2,034.84 | 2,120.34 | 1,730.87 |
| II | | Current liabilities | | | | |
| | | Financial liabilities | | | | |
| | | (i) Borrowings | 17 | 631.82 | 508.06 | 223.91 |
| | 1 | (ii) Lease Liabilities | 30 | 20.45 | 19.12 | 18.26 |
| | | (iii) Trade payables | 18 | | | |
| | | (a) Total outstanding dues of Micro Enterprises and Small Enterprises | | 15.08 | 22.81 | |
| | | (b) Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises | | 153.69 | 181.31 | 165.33 |
| | | CA Other Constitution | | | | 505.000 |
| | | (iv) Other financial liabilities | 19 | 142.40 | 145.36 | 107.20 |
| | | Other current liabilities Provisions | 20 | 31.15 | 32.28 | 35.25 |
| | | Provisions Total current liabilities | 21 . | 0.59 | 62.10 | 0.06 |
| | | | | 995.18 | 971.05 | 550.01 |
| | 3 | Total Equity and Liabilities | | 4,859.66 | 4,260.23 | 3,087.71 |

The above statement should be read with significiant accounting policies forming part of the Restated Consolidated Financial Information in Annexure V, and Notes to Restated Consolidated Financial Information in Annexure VI.

As per our report of even date

For R.Nagpal Associates

CHARTERED ACCOUNTANTS sypal Associ Firm Registration No.002626N

(Rohit Mehra) Partner M. No. 093910

Place: Noida Dated: 😊 🗲 On behalf of the Board of Directors

Yatharth Hospital & Trauma Care Services Limited

CIN:U85110DL2008PLC174706

Dr. Ajay Kumar Tyagi Chairman & Whole-Time Director DIN:01792886

Dr. Kapil Kumar **Managing Director** DIN: 01818736

Amit Kumar Singh Chief Executive Officer PAN: BFZPS6168A

CS & Compliance Officer M. No 51166

Pankaj Prabhakar CFO

Annexure II

Restated Consolidated Statement of Profit & Loss

(All amounts in million, unless otherwise stated)

| | Particulars | Note No | For the year ended March 31, 2023 | For the year ended March 31, 2022 | For the year ended March 31, 2021 |
|------|---------------------------------------------------------------------------------------------------------------|-----------------|--------------------------------------|--------------------------------------|--------------------------------------|
| | Income | | | | |
| I | Revenue from operations | 22 | 5,202.93 | 4,009.37 | 2,286.74 |
| II | Other income | 23 | 28.07 | 16.49 | 5.15 |
| Ш | Total income (I+II) | · · | 5,231.00 | 4,025.86 | 2,291.89 |
| IV | Expenses: | | | | |
| | Cost of Material Consumed | 24 | 929.35 | 813.28 | 463.18 |
| | Employee benefits expense | 25 | 919.30 | 804.68 | 466,88 |
| | Finance cost | 26 | 213.87 | 214.86 | 188.44 |
| | Depreciation and amortization expenses | 27 | 275.07 | 278.68 | 205.60 |
| | Other expenses | 28 | 2,016.63 | 1,283.29 | 686.56 |
| | Total expenses | | 4,354.22 | 3,394.80 | 2,010.66 |
| V | Profit / (Loss) before tax (III-IV) | 5)# | 876.78 | 631.06 | 281.23 |
| VI | Tax expense: | 50 . | | | 201120 |
| | (1) Current tax | | 246.66 | 180.09 | 50.37 |
| | (2) Income tax of earlier years | | 1.61 | - | |
| | (3)MAT credit availed/reversed | | 11.03 | 18.02 | (16.63) |
| | (4) Deferred tax (net) | | (40.19) | (8.68) | 51.61 |
| | Total tax expenses | | 219.10 | 189.44 | 85.36 |
| VII | Profit/(Loss) for the year (V-VI) | | 657.68 | 441.62 | 195.88 |
| VIII | Other comprehensive income | | | 4 | |
| | (a)(i) Items that will not be reclassified to profit or loss | | | - | |
| | (ii)Income tax relating to items that will not be reclassified to profit or loss | | | | - |
| | (b) (i) Items that will be reclassified to profit or loss | | 4.01 | 3.77 | 0.02 |
| | (ii)Income tax relating to items that will be reclassified to profit or loss | | (0.90) | (1.10) | (0.01) |
| | Other comprehensive income for the year | _ | 3.11 | 2.67 | 0.02 |
| IX | Total comprehensive income (VII+VIII)(Comprising Profit (Loss) and Other Comprehensive Income for the period) | | 660.79 | 444.30 | 195.90 |
| | Des Gill and South and Carlotte | - | | | |
| | Profit/(Loss) for the year attributable to To the Owners of the company | | 657.68 | 441.62 | 181.60 |
| | Non Controlling Interest | | - | - | 14.28 |
| | Other comprehensive income for the period/year attributable to: | | | | |
| | To the Owners of the company | | 3,11 | 2.67 | 0.02 |
| | Non Controlling Interest | | * | - | - |
| | Total Comprehensive Income for the period attributable to: | | | | |
| | To the Owners of the company | | 660.78 | 444.30 | 181.62 |
| х | Non Controlling Interest | | ¥ | - | 14.28 |
| A | Earnings per equity share - Rs (1) Basic | 29 | 10.09 | 6.78 | 2.77 |
| | (2) Diluted | 43 | 10.09 | 6.78 | 2.77 |
| | | | 10.07 | 0.70 | 2.11 |

The above statement should be read with significiant accounting policies forming part of the Restated Consolidated Financial Information in Annexure V, and Notes to Restated Consolidated Financial Information in Annexure VI.

As per our report of even date

For R.Nagpal Associates CHARTERED ACCOUNTANTS

Firm Registration No.002626N

Rew Delhi

(Rohit Mehra)

Partner

M. No. 093910 Place: Noida

On behalf of the Board of Directors

Yatharth Hospital & Trauma Care Services Limited

ÇIN:U85110DL2008PLC174706

Dr. Ajay Kumar Tyagi Chairman & Whole-Time

DIN:01792886

Dr. Kapil Kumar **Managing Director**

DIN: 01818736

Amit Kumar Singh Chief Executive

Officer

PAN: BFZPS6168A

Ritesh Mishra CS & Compliance Officer M. No 51166

CFO

Annexure III

Restated Consolidated Statement of Cash Flow

(All amounts in million, unless otherwise stated)

| | Particulars | For the year ended March 31, 2023 | For the year ended March 31, 2022 | For the year ended March 31, 2021 |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| | Cash flow from operating activities | | | |
| 1 | Profit/(Loss) before tax and exceptional items Adjustments for: | 876.78 | 631.06 | 281.23 |
| | Depreciation and Amortisation expense | 275.07 | 278.68 | 205.60 |
| | Finance costs | 213.87 | 214.86 | 188.44 |
| 1 | nterest on bank deposits | (1.41) | (1.02) | (0.37) |
| | Operating profit before working capital changes | 1,364.30 | 1,123.58 | 674.89 |
| | Working capital adjustments | | | |
| | Increase)/Decrease in Trade receivables | (221.06) | (487.73) | (198.62) |
| | Increase)/Decrease in Inventories | (8.74) | (18.06) | (5.31) |
| (, | Increase)/Decrease in Financial Assets and other Current and Non-Current Assets | (91.01) | 25.26 | (8.45) |
| 11 | ncrease (Decrease) in Financial Liabilities & Other Current and Non-Current Liabilities ncrease (Decrease) in Current and Non current Provisions | (39.43) | 73.36 | (3.42) |
| | Cash generated from operations | 7.75 | 13.14 | 0.11 |
| | ************************************** | 1,011.81 | 729.56 | 459.21 |
| | ncome tax (paid)/Refund (net) | (373.98) | (130.21) | (22.48) |
| P | let cash inflow from operating activities'A' | 637.84 | 599,35 | 436.73 |
| В. С | Cash flow from Investing activities | | | |
| P | urchase of Property, plant and equipment including capital work in progress and capital advances | | | |
| an | d capital creditors | (198.14) | (131.34) | (201.35) |
| | cquistion of Fixed Assets-Net of Liabilities On account of Business Combination | - | (262.30) | (201.00) |
| | vestment in Subsidiary | | (126.91) | (11.31) |
| | nterest on Bank deposits | 1.41 | 1.02 | 0.37 |
| In | evestment in bank deposits having original maturity of more than three months | (6.37) | (2.22) | (0.10) |
| N | et cash used in investing activities`B' | (203.10) | (521.75) | (212.38) |
| C. C | ash flow from Financing activities | | | |
| | et movement of long term borrowings and short term borrowings | 26.20 | 202 (2 | (0.07) |
| | nance Cost | 36.39 | 203.62 | (2.07) |
| | | (213.87) | (214.86) | (188.44) |
| N | et cash used in financing activities`C' | (177.48) | (11.24) | (190.50) |
| N | et increase/(Decrease) in cash or cash equivalent (A+B+C) | 257.25 | 66.37 | 33.85 |
| | ash & cash equivalent at the commencement of the period | 117.07 | | |
| | dd: On account of Business Combination | 117.07 | 50.00 | 16.15 |
| | ash & cash equivalent at the end of the period | 374,32 | 0.71 | 50.00 |
| Re | econciliation of cash and cash equivalents as per the cash flow statement | 374.32 | 117.07 | 50.00 |
| | alance with banks in current accounts | 356.80 | 112.64 | 45.00 |
| | ash in hand | 15.45 | 113.64 2.93 | 45.82 4.18 |
| | ank Deposits with maturing with in 3 months- pledged with banks | 2.08 | 0.51 | 4.10 |
| | otal | 374.32 | 117.07 | 50,00 |
| 7.0 | • | 314.32 | 117,07 | 20,00 |

For R.Nagpal Associates

CHARTERED ACCOUNTANTS

Firm Registration No.002626N ASS

Partner

M. No. 093910

Place: Noida Dated: 🟉 S

(Rohit Mehra) New Delhi On behalf of the Board of Directors

Yatharth Hospital & Trauma Care Services Limited

CIN:U85110DL2008PLC174706

Dr. Ajay Kumar Tyagi Chairman & Whole-**Time Director**

CS & Compliance Officer

DIN:01792886

M. No 51166

Dr. Kapil Kumar **Managing Director**

DIN: 01818736

Amit Kumar Singh **Chief Executive** Officer PAN: BFZPS6168A

Pankaj Prabhakar

CFO

Restated Consolidated Statement of changes in Equity

(All amounts in million, unless otherwise stated) Equity Share Capital:

| Particulars | As at March | 31, 2023 | As at March 3 | 31, 2022 | As at March 31, 2021 | |
|-----------------------------------------------------------|------------------|---------------------|------------------|----------|----------------------|--------|
| a michais | Number of Shares | Amount | Number of Shares | Amount | Number of Shares | Amount |
| Shares outstanding at the beginning of the reporting year | 65.52 | 655.17 | 16,38 | 163.79 | 16.38 | 163.79 |
| Change in equity share capital during the year | | 1/800-1/200-1/200-1 | 49.14 | 491.38 | - | - |
| Share outstanding at the end of the year | 65.52 | 655.17 | 65,52 | 655.17 | 16.38 | 163.79 |

Other Equity:

| Particulars | Securities Premium Account | Retained Earnings | Other Comprehensive Income | Equity attributable to shareholders of the company | Equity attributable to Non Controlling Interest | Total Equity |
|-------------------------------------------------------------------------|-------------------------------|----------------------|----------------------------------|-------------------------------------------------------------|----------------------------------------------------------|--------------|
| Balance at 1st April, 2020 | 176.60 | 202.53 | (0.00) | 379.13 | 77,79 | 456.92 |
| Surplus in the statement of profit and loss transferred during the year | - | 181.60 | | 181.60 | 4.49 | 186.09 |
| Restated Balances at the closing of the year | 176.60 | 384.13 | (0.00) | | 82.28 | 643.01 |
| Total Comphensive Income for the current year | | | 0.02 | 0.02 | | 0.02 |
| Balance at 31st March, 2021 | 176.60 | 384.13 | 0.02 | 560,76 | 82.28 | 643.04 |

| Particulars | Securities Premium Account | Retained Earnings | Other Comprehensive Income | Equity attributable to shareholders of the company | Equity attributable to Non Controlling Interest | Total Equity |
|-------------------------------------------------------------------------|-------------------------------|----------------------|----------------------------------|-------------------------------------------------------------|----------------------------------------------------------|--------------|
| Balance at 1st April, 2021 | 176.60 | 384.13 | 0.02 | 560.76 | 82.28 | 643.04 |
| Surplus in the statement of profit and loss transferred during the year | | 441.62 | <u>.</u> | 441.62 | - | 441.62 |
| Movement on account of equity purchase by Company | | - | | - | (82.28) | (82,28) |
| Restated Balances at the closing of the year | 176.60 | 825.76 | 0.02 | 1,002.38 | - 1 | 1,002,38 |
| Issue of Bonus Shares | (176.60) | (314.77) | | (491.38) | | (491.38) |
| Total Comphensive Income for the current year | | | 2.67 | 2.67 | | 2.67 |
| Balance at 31st March, 2022 | | 510.98 | 2.70 | 513.68 | - | 513.68 |

| Particulars | Securities Premium Account | Retained Earnings | Other Comprehensive Income | Equity attributable to shareholders of the company | Equity attributable to Non Controlling Interest | Total Equity |
|-------------------------------------------------------------------------|-------------------------------|----------------------|----------------------------------|-------------------------------------------------------------|----------------------------------------------------------|--------------|
| Balance at 1st April, 2022 | | 510.98 | 2.70 | 513.68 | | 513.68 |
| Surplus in the statement of profit and loss transferred during the year | | 657.68 | | 657.68 | | 657.68 |
| Restated Balances at the closing of the year | | 1,168,66 | 2.70 | 1,171.36 | | 1,171.36 |
| Issue of Bonus Shares | | - | | -, | | ., |
| Total Comphensive Income for the current year | | - | 3.11 | 3.11 | | 3.11 |
| Balance at 31st March, 2023 | - | 1,168.66 | . 5.81 | 1,174.47 | - | 1,174.47 |

For Reserves see Note No-13

The above statement should be read with significiant accounting policies forming part of the Restated Consolidated Financial Information in Annexure V. and Notes to Restated Consolidated Financial Information in Annexure VI.

As per our report of even date attached to the financial statement

New Delhi

For R.Nagpal Associates

For R.Nagpal Associated Chartered Accountants
Firm Registration No. 002626ND all ASS

(Rohit Mehra)

Partner

Place: Noida Dated:

M. No. 093910

For and on behalf of the Board Yatharth Hospital & Trauma Care Services Limited

Dr. Ajay Kumar Tyagi Chairman & Whole-Time Director

DIN:01792886

Dr. Kapil Kumar Managing Director DIN: 01818736

Chief Executive Officer PAN: BFZPS6168A

Ritesh Mish CS & Compliance Officer

M. No 51166

CFO

Annexure V
Notes to Restated Consolidated Financial Information

1 General Information

The Restated Consolidated Financial Information comprise financial statements of Yatharth Hospital & Trauma Care Services Limited (formerly known as Yatharth Hospital & Trauma Care Services Private Limited) (the Holding Company) and its subsidiaries (collectively, the Group) for each year ended March 31, 2023, March 31, 2022 and March 31, 2021.

The Holding Company is a Company domiciled in India, with its registered office situated at JA, 108 DLF, Tower A, Jasola District, Centre South Delhi, Delhi – 110025, India. The Holding Company was incorporated on February 28, 2008 under the provisions of the Companies Act, 1956, then applicable in India. The Group is primarily involved in the business of providing healthcare services, operating hospitals and other allied services, as may be required for the provision of healthcare services.

The Restated Financial statements were authorised for issue in accordance with a resolution of the Directors on 05th July, 2023.

2 Basis of Preparation of Restated Consolidated Financial Information

2.1 Statement of Compliance

The consolidated restated financial information of the Group comprise of the restated consolidated statement of Assets and Liabilities as at March 31, 2023, March 31, 2022 and March 31, 2021, the restated consolidated statement of profit and loss (including other comprehensive income), restated consolidated statement of changes in equity and the restated consolidated statement of cash flows for the year ended March 31, 2023, March 31, 2022 and March 31, 2021 and the summary of significant accounting policies and explanatory notes (collectively, the 'Restated Consolidated Financial Information').

These Restated Consolidated Financial Information of the Group comprise of the restated consolidated statement of Assets and Liabilities as at March 31, 2023, March 31, 2022 and March 31, 2021, the restated consolidated statement of profit and loss (including other comprehensive income), restated consolidated statement of changes in equity and the restated consolidated statement of cash flows for the year ended March 31, 2023, March 31, 2022 and March 31, 2021 and the summary of significant accounting policies and explanatory notes have been prepared by the management for the purpose of preparation of the restated financial information as required under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("ICDR Regulations") issued by the Securities and Exchange Board of India ('SEBI') for the purpose of inclusion in the Offer Document') prepared by the Company in connection with its proposed Initial Public Offer ("Offer") in terms of the requirements of:

- a) Section 26 of Part I of Chapter III of the Companies Act, 2013 ("the Act");
- b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended; and
- c) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India (ICAI) (the "Guidance Note").

The restated financial information has been compiled by the Management of the Company from:

a) Audited Consolidated Ind AS Financial Statements of the Group as at and for the year ended March 31, 2023 prepared by the Management in accordance with the Ind AS, as prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as amended, and other accounting principles generally accepted in India, which has been approved by the Board of Directors at their meeting held on June 17th 2023.





Annexure V Notes to Restated Consolidated Financial Information

- b) Audited Consolidated Ind AS Financial Statements of the Group as at and for the year ended March 31, 2022 prepared by the Management in accordance with the Ind AS, as prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as amended, and other accounting principles generally accepted in India, which has been approved by the Board of Directors at their meeting held on August 04th 2022:
- c) Audited Special Purpose Consolidated Ind AS Financial Statements of the Group as at and for the year ended March 31, 2021 prepared by the Management in accordance with the Ind AS, as prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as amended, and other accounting principles generally accepted in India, which has been approved by the Board of Directors at their meeting held on March 25, 2022

The restated financial Information is presented in Indian Rupees (INR) millions, except where otherwise indicated.

2.2 Basis of measurement

The Restated Consolidated Financial Information have been prepared on accrual basis and under historical cost convention, except for certain financial assets and liabilities which are measured at fair value.

The functional and presentation currency of the Company is Indian Rupee ("INR") which is the currency of the primary economic environment in which the Company operates.

All amounts disclosed in the Restated Consolidated Financial Information and notes have been rounded off to the nearest "million" with two decimals, unless otherwise stated. Transactions and balances with values below the rounding off norm adopted by the group have been reflected as "0" in the relevant notes to Restated financial statements.

2.3 Basis of consolidation

Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, the income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit and loss from the date the Company gains control until the date when the Company ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies.

All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.





Annexure V Notes to Restated Consolidated Financial Information

The Restated Consolidated Financial Information includes the financial information of Yatharth Hospital & Trauma Care Services Limited and its subsidiaries as set out below:

| | Country of | Ownership Interest (in %) (Direct) | | | |
|---------------------------------------------------------------------|---------------|------------------------------------|-----------|----------|--|
| Name of Company | Incorporation | March 31, | March 31, | March | |
| | meorporation | 2023 | 2022 | 31, 2021 | |
| AKS Medical & Research Centre Pvt. Ltd. | India | 100% | 100% | 80.31% | |
| Sanskar Medica India Limited | India | 100% | 100% | 100% | |
| Ramraja Multispeciality Hospital & Trauma Centre Private Limited | India | 100% | 100% | - | |

2.4 Use of estimates

The preparation of Restated Consolidated Financial Information in conformity with Ind AS requires the Management to make estimates and assumptions that affect the reported amount of assets and liabilities as at the Balance Sheet date, reported amount of revenue and expenditure for the year and disclosures of contingent liabilities as at the Balance Sheet date. The estimates and assumptions used in the accompanying Restated Financial statements are based upon the Management's evaluation of the relevant facts and circumstances as at the date of the Restated Consolidated Financial Information. Actual results could differ from these estimates. Estimates and underlying assumptions are reviewed on a year basis. Revisions to accounting estimates, if any, are recognized in the year in which the estimates are revised and in any future years affected.

3 Summary of Significant accounting policies

3.1 Revenue Recognition

The Company's revenue from medical and healthcare services comprises of income from hospital services and sale of pharmacy items.

Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.

Income from hospital services comprises of fees charged for inpatient and outpatient hospital services. The performance obligations for this stream of revenue include accommodation, surgery, medical/clinical professional services, food and beverages, investigations and supply of pharmaceutical and related products.

Revenue is measured based on the transaction price, which is the fixed consideration adjusted for components of variable consideration which constitutes discounts, estimated disallowances and any other rights and obligations as specified in the contract with the customer. Revenue also excludes taxes collected (if any) from customers and deposited back to the respective statutory authorities.

Revenue is recognised at the point in time for the outpatient hospital services, when the related services are rendered at the transaction price. With respect to the inpatients hospital services, the revenue is recognized at the transaction price on such patients where the hospital services are rendered completely.

Revenue from sale of pharmacy and food and beverages (other than hospital services), where the performance obligation is satisfied at a point in time, is recognised when the control of goods is transferred to the customer.



Annexure V Notes to Restated Consolidated Financial Information

The company applies the most likely amount method or the expected value method to estimate the variable consideration in the contract. The selected method that best predicts the amount of variable consideration is primarily driven by the number of volume thresholds contained in the contract. The most likely amount is used for those contracts with a single volume threshold, while the expected value method is used for those with more than one volume threshold. The company then applies the requirements on constraining estimates in order to determine the amount of variable consideration that can be included in the transaction price and recognised as revenue.

Contract assets represents value to the extent of medical and healthcare services rendered to the patients who are undergoing treatment/ observation on the balance sheet date and is not billed as at the balance sheet date.

Other Income

Interest on deposits, loans and debt instruments are measured at amortized cost. interest income is recorded using the Effective Interest Rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortized cost of a financial liability.

3.2 Property, Plant and Equipment

Property, Plant and Equipment (PPE) are stated at original cost of acquisition including incidental expenses and all the borrowing costs, which are directly attributable to the acquisition of assets and installation of the concerned assets. PPE are shown net of accumulated depreciation.

The Company has elected to continue with the carrying value for all of its Property, Plant and Equipment recognised as of April 01, 2018 (date of transition to Ind AS) measured as per the previous GAAP and used that carrying value as its deemed cost as at the date of transition.

Capital work in progress is stated at cost, net of accumulated impairment loss, if any.

Depreciation has been charged as per new rules as provided by The Companies Act, 2013. For PPE acquired during the year, depreciation is provided on pro rata basis from the date the assets were put to use. The carrying amount of a property, plant and equipment is de-recognised when no future economic benefits are expected from its use or on disposal.

Depreciation on property, plant and equipment is provided on written down value method based on estimated useful life of assets as prescribed in part C of schedule II to the Companies Act, 2013.

| Assets | Useful Lives | |
|------------------------|--------------|--|
| Building | 60 Years | |
| Plant and Machinery | 5-15 years | |
| Furniture and Fittings | 8 years | |
| Air-conditioners | 10 years | |
| Electric installations | 10 years | |
| Office Equipments | 5 years | |
| Vehicles | 8 years | |
| Computers | 3 years | |

The property, plant and equipment acquired under finance leases, if any, is depreciated over the asset's useful life or over the shorter of the asset's useful life and the lease term if there is no reasonable certainty that the Company will obtain ownership at the end of the lease term.





Annexure V Notes to Restated Consolidated Financial Information

Freehold land is not depreciated. Lease hold land is depreciated over the balance period of lease, once the building or any other asset erected over such period of land is put to use.

Based on the planned usage of certain specific assets and technical assessment, the management has estimated the useful lives of Property, plant and equipment as below:

- Individual asset not exceeding Rs. 5,000 have been fully depreciated in the year of purchase.
- Leasehold improvements are amortized over the period of the lease or estimated useful life, whichever
 is shorter.

The residual values, useful lives, and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

3.3 Taxes on Income

Tax Expenses:

Income Tax expense comprises of current tax and deferred tax charge or credit. Provision for current tax is made with reference to taxable income computed for the financial year for which the financial statements are prepared by applying the tax rates as applicable.

Current Tax - Current Income tax relating to items recognized outside the profit and loss is recognized outside the profit and loss (either in other comprehensive income or in other component of equity)

MAT- Minimum Alternate Tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The company recognizes MAT credit available as an asset only to the extent there is convincing evidence that the company will pay normal income tax during the specified period, i.e., the period for which MAT Credit is allowed to be carried forward. In the year in which the Company recognizes MAT Credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternate Tax under the Income Tax Act, 1961, the said asset is created by way of credit to the statement of Profit and Loss and shown as "MAT Credit Entitlement." The Company reviews the "MAT Credit Entitlement" asset at each reporting date and writes down the asset to the extent the company does not have convincing evidence that it will pay normal tax during the sufficient period.

Deferred Tax:-Deferred tax is provided using the liability method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purpose at reporting date i.e. timing difference between taxable income and accounting income. Deferred income tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that includes the enactment or the substantive enactment date. A deferred income tax asset is recognized to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences and tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed as at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will not be available against which deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets are recognized for the unused tax credit to the extent that it is probable that taxable profits will be available against which the losses will be utilized. Significant management judgement is





Annexure V Notes to Restated Consolidated Financial Information

required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

3.4 Borrowing Costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

3.5 Leases

Right of Use Assets

The Company recognizes a right-of-use asset, on a lease by-lease basis, to measure that right-of-use asset an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the balance sheet immediately before the date of initial application.

The cost of right-of-use assets includes the amount of lease liabilities recognised. Initial direct costs incurred and lease payments made at or before the commencement date less any lease incentives received, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment test.

Lease Liabilities

The Company recognise a lease liability at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate. The lease payments include fixed payments (including insubstance fixed payments) less any lease incentives receivable, variable lease payments that depend on a lease by lease basis. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable.

Short-term Leases and leases of low-value assets

The company applies the short-term lease recognition exemption to its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases that are considered of low value. Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

3.6 Inventory

Inventories are stated at lower of cost or net realisable value. Cost of Inventories comprises of cost of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Closing stock cost is determined on FIFO basis.





Annexure V Notes to Restated Consolidated Financial Information

3.7 Employee Benefits

The undiscounted amount of short-term employee benefits i.e. wages and salaries, bonus, incentive and annual leave etc. expected to be paid in exchange for the service rendered by employees are recognized as an expense except in so far as employment costs maybe included within the cost of an asset during the period when the employee renders the services.

Retirement benefit in the form of provident fund and pension contribution is a defined contribution scheme and is recognized as an expense except in so far as employment costs may be included within the cost of an asset.

Gratuity is a defined benefit obligation. The liability is provided for on the basis of actuarial valuation made at the end of each financial year. The actuarial valuation is done as per Projected Unit Credit method.

Re-measurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to profit or loss through OCI in the period in which they occur. Re measurements are not reclassified to profit or loss in subsequent periods.

3.8 Foreign Exchange Transactions

These financial statements are presented in Indian Rupees (INR), which is the Company's functional currency.

Transactions in foreign currency are recorded on initial recognition at the spot rate prevailing at the time of the transaction.

At the end of each reporting period:

- Monetary items (Assets and Liabilities) denominated in foreign currencies are retranslated at the rates prevailing at that date.
- Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined.
- Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated Exchange differences on monetary items are recognized in profit or loss in the period in which they arise.

3.9 Fair Value Measurement: -

The Company measures financial instruments at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company. The fair value of an

raum

Annexure V Notes to Restated Consolidated Financial Information

asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 Quoted (unadjusted) market prices in active markets for identical assets or liabilities.
- Level 2 Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and the risks of the asset or liability and the level of the fair value hierarchy as explained above.

3.10 Financial Instrument

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

a) Recognition

The company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument

b) Measurement

Financial assets

A financial asset is measured at

- amortized cost or
- fair value either through other compressive income or through profit or loss

ii. Financial liability





Annexure V Notes to Restated Consolidated Financial Information

A financial liabilities is measured at amortized cost using the effective interest method or fair value through profit or loss.

iii. Initial recognition and measurement:

All financial assets and liabilities are recognized at fair value at initial recognition, plus or minus, any transaction cost that are directly attributable to the acquisition or issue of financial assets and financial liabilities that are not at fair value through profit or loss.

iv. Subsequent measurement

Financial assets as subsequent measured at amortized cost or fair value through other comprehensive income (FVOCI) or fair value through profit or loss (FVTPL) as the case may be.

Financial liabilities as subsequent measured at amortized cost or fair value through profit or loss.

c) Financial Assets

i. Trade Receivables

Trade receivables are the contractual right to receive cash or other financial assets and recognized initially at fair value. Subsequently measured at amortized cost (Initial fair value less expected credit loss). Expected credit loss is the difference between all contractual cash flows that are due to the company and all that the company expects to receive (i.e. all cash shortfall), discounted at the effective interest rate.

ii. Equity investments -Investment in Subsidiary, associates & Joint venture

Investment in Subsidiary, associates & Joint venture is carried at cost as per Ind AS27

All other equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognised by an acquirer in a business combination to which Ind AS103 applies are classified as at FVTPL. For all other equity instruments, the company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company makes such election on an instrument by- instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at Fair value to other comprehensive income (FVTOCI), then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to P&L, even on sale of investment. However, the company may transfer the cumulative gain or loss within equity.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the P&L.

iii. Cash and cash Equivalents:-

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.





Annexure V
Notes to Restated Consolidated Financial Information

iv. Impairment of Financial Assets:-

The Company recognizes loss allowances using the expected credit loss (ECL) model for the financial assets which are not fair valued through profit or loss. Loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime ECL. For all other financial assets, expected credit losses are measured at an amount equal to the 12-month ECL, unless there has been a significant increase incredit risk from initial recognition in which case those are measured at lifetime ECL. The amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognised is recognized as an impairment gain or loss in profit or loss.

d) Financial liabilities

i. Trade payables

Trade payables represent liabilities for goods and services provided to the Company prior to the end of financial year and which are unpaid. Trade payables are presented as current liabilities unless payment is not due within 12 months after the reporting period or not paid/payable within operating cycle. They are recognised initially at their fair value and subsequently measured at amortized cost using the effective interest method.

ii. Borrowings

Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period. Where there is a breach of a material provision of a long-term loan arrangement on or before the end of the reporting period with the effect that the liability becomes payable on demand on the reporting date, the company does not classify the liability as current, if the lender agreed, after the reporting period and before the approval of the financial statements for issue, not to demand payment as a consequence of the breach.

iii. Equity Instruments

An equity instrument is any contract that evidences a residual interest in the assets of company after deducting all of its liabilities. Equity instruments are recognised at the proceeds received, net of direct issue costs.

e) Derecognition of financial instrument

The company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition under Ind AS 109. A financial liability (or a part of a financial liability) is derecognized from the company's balance sheet when the obligation specified in the contract is discharged or cancelled or expires.

f) Offsetting of financial instruments:

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously





Annexure V Notes to Restated Consolidated Financial Information

g) Financial guarantee

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the guarantee. Subsequently, the liability is measured at the higher of the amount of loss allowance determined as per impairment requirements of IND AS 109 and the amount recognised less cumulative amortization.

3.11 Operating cycle:-

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

3.12 Earning Per Share

The Earning per share is computed in accordance with the IND AS 33. Basic earnings per share are calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

3.13 Provisions, Contingent Liabilities and Contingent Assets

I. A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements. Contingent liabilities, if material, are disclosed by way of notes and contingent assets, if any, is disclosed in the notes to financial statements.

Contingent liabilities, which according to the management are not expected to materialize are not recognized in the financial statements are disclosed in the notes to the accounts. Contingent assets are neither recognized nor disclosed in financial statements.

II. A provision is recognized, when Company has a present obligation (legal or constructive) as a result of past events and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, in respect of which a reliable estimate can be made for the amount of obligation. The expense relating to the provision is presented in the profit and loss net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pretax rate that reflects, when appropriate, the risks.

3.14 Segment Reporting

The company is mainly into the business of rendering hospital services. Other services like sale of medicine etc are ancillary to the main services and thus the only business segment, in terms of IND AS 108 and therefore no separate reporting under 'Segment Reporting' is required.





Annexure V
Notes to Restated Consolidated Financial Information

3.15 Cash flows

Cash flows are reported using the indirect method, where by profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The Cash flows from operating, investing and financing activities of the company are segregated

3.16 Impairment of Assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pretax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

Impairment losses of continuing operations, including impairment on inventories, are recognised in the statement of profit and loss, except for properties previously revalued with the revaluation surplus taken to Other Comprehensive Income (OCI). For such properties, the impairment is recognised in OCI up to the amount of any previous revaluation surplus.

For assets other than goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit or loss unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.

Goodwill is tested for impairment as at each Balance Sheet date and when circumstances indicate that the carrying value may be impaired.

Impairment is determined for goodwill by assessing the recoverable amount of each CGU (or group of CGUs) to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognised. Impairment losses relating to goodwill cannot be reversed in future periods.

Intangible assets with indefinite useful lives are tested for impairment annually as at each Balance sheet date at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired.

When an impairment loss subsequently reverses, the carrying amount of the asset (or a cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying





Annexure V Notes to Restated Consolidated Financial Information

amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or Loss.

3.17 Current and non-current assets and liabilities

All financials assets and liabilities maturing with-in the time period of operating cycle which at present is 1 year are considered current assets or liabilities. All assets and liabilities, not being current are considered noncurrent assets or liabilities.

3.18 Expenditure during construction period:

Assets in the course of construction are capitalized in the assets and treated as capital work in progress and upon commissioning of project the assets are capitalised and transferred to appropriate category of PPE. At the point when an asset is operating at management's intended use, the cost of construction is transferred to appropriate category of PPE.





Annexure VI
Notes to Restated Consolidated Financial Information
(All amounts in million, unless otherwise stated)
2. Property, Plant & Equipment

| | Lease Hold | Free Hold | | Plant & | Furniture & | Office | | |
|------------------------------------------------------------|------------|------------------|-----------|-----------|----------------|---------------|----------|----------|
| Particulars | Land* | Land | Buildings | Machinery | Fittings | Equipments | Vehicles | Total |
| Cost as at 1st April, 2020 | 180.31 | - | 1,278.21 | 641.60 | 27.47 | 262.54 | 43.21 | 2,433.33 |
| Additions | - | = | 504.09 | 226.86 | 17.68 | 51.47 | 17.32 | 817.43 |
| Additions through business combination | 7 | 5 | | - | - | - | | - |
| Disposals | | | - 2 | 1.5 | | - | - | - |
| Cost as at 31st March, 2021 (A) | 180.31 | - | 1,782.30 | 868,46 | 45.15 | 314.02 | 60.53 | 3,250.76 |
| Cost as at 1st April, 2021 | 180.31 | 2 | 1,782.30 | 868.46 | 45.15 | 314.02 | 60.53 | 3,250.76 |
| Additions | - | * | 27.08 | 23.84 | 4.54 | 25.48 | 16.45 | 97.39 |
| Additions through business combination | | 25.31 | 228.09 | 182.92 | 30.43 | 142.89 | 7.54 | 617.17 |
| Disposals | - | - | 2.5 | | | - | - | - |
| Cost as at 31st March, 2022 (C) | 180.31 | 25.31 | 2,037.46 | 1,075.22 | 80.12 | 482.39 | 84.52 | 3,965.32 |
| Cost as at 1st April, 2022 | 180.31 | 25.31 | 2,037.46 | 1,075.22 | 80.12 | 482.39 | 84.52 | 3,965.32 |
| Additions | E | - | 48.32 | 149.72 | 11.90 | 18.50 | 0.84 | 229.28 |
| Additions through business combination | - | - | 7.4 | - | 19 - 11 | 1 <u>=</u> 1; | 0.20 | |
| Disposals | * | - | - | - | | | | - |
| Cost as at 31st March, 2023 (E) | 180.31 | 25.31 | 2,085.78 | 1,224.93 | 92.02 | 500.89 | 85.35 | 4,194.60 |
| | | | | | | | | |
| Accumulated Depreciation | | | | | | | | |
| Accumulated Depreciation as at 1st April, 2020 | 3.45 | - | 150.62 | 312.35 | 11.73 | 131.15 | 28.08 | 637.38 |
| Depreciation for the year | 2.17 | - | 54.86 | 82.74 | 4.95 | 33.61 | 6.69 | 185.01 |
| Disposals | | - | - | - | (=) | - | - | - |
| Accumulated Depreciation as at 31st March, 2021 (B) | 5.62 | - | 205.48 | 395.08 | 16.68 | 164.76 | 34.76 | 822.39 |
| Accumulated Depreciation as at 1st April, 2021 | 5.62 | - | 205.48 | 395.08 | 16.68 | 164.76 | 34.76 | 822.39 |
| Depreciation for the year | 2.17 | 12 | 100.34 | 99.15 | 8.99 | 37.32 | 10.67 | 258.64 |
| Depreciation on business combinations | - | 141 | 49.54 | 124.79 | 22.99 | 101.86 | 7.31 | 306.49 |
| Disposals | | | (¥) | | - | - | (46) | - |
| Accumulated Depreciation as at 31st March, 2022 (D) | 7.79 | - | 355,36 | 619.03 | 48.66 | 303.94 | 52.74 | 1,387.51 |
| | | | | | | | | |
| accumulated Depreciation as at 1st April, 2022 | 7.79 | (-) | 355.36 | 619.03 | 48.66 | 303.94 | 52.74 | 1,387.51 |
| Depreciation for the year | 2.17 | - | 82.21 | 105.98 | 9.57 | 44.21 | 9.87 | 254.00 |
| Depreciation on business combinations | # <u>*</u> | - | - | - | = | 8 | - | - |
| Pisposals | 100 | - | - | 2 | | - | - | _ |
| eccumulated Depreciation as at 31st March, 2023 (F) | 9,96 | | 437.57 | 725.00 | 58.23 | 348.14 | 62.61 | 1,641.51 |
| | | | | | | | | |
| let Carrying Amount | | | | | | | | |
| s at 31st March, 2021 (A-B) | 174.68 | - | 1,576.82 | 473.37 | 28.47 | 149.26 | 25.77 | 2,428.37 |
| s at 31st March, 2022 (C-D) | 172.51 | 25.31 | 1,682.10 | 456.19 | 31.46 | 178.45 | 31.78 | 2,577.81 |
| s at 31st March, 2023 (E-F) | 170.34 | 25.31 | 1,648.21 | 499.93 | 33.80 | 152.75 | 22.75 | 2,553.09 |
| Leasehold Land is for a perpetual lease period of 90 Years | | | | | | | | |





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

| 3. Intangible Assets | | |
|-----------------------------------------------------------|-------------------|-------|
| Particulars | Computer Software | Total |
| Cost as at 1st April, 2021 | | |
| Additions | _ | - |
| Additions through business combination | 1.12 | 1.12 |
| Disposals | | - |
| Cost as at 31st March, 2022 (A) | 1.12 | 1.12 |
| Cost as at 1st April, 2022 | 1.12 | 1.12 |
| Additions | - | - |
| Additions through business combination | - | _ |
| Disposals | · | - |
| Cost as at 31st March, 2023 (C) | 1.12 | 1.12 |
| Accumulated Depreciation | | |
| Accumulated Depreciation as at 1st April, 2021 | - | |
| Depreciation on business combination | 1.05 | 1.05 |
| Disposals | 22 <u>-</u> | |
| Accumulated Depreciation as at 31st March, 2022 (B) | 1.05 | 1.05 |
| Accumulated Depreciation as at 1st April, 2022 | 1.05 | 1.05 |
| Depreciation | 0.07 | 0.07 |
| Disposals | - | - |
| Accumulated Depreciation as at 31st March, 2023 (D) | 1.12 | 1.12 |
| Net Carrying Amount | | |
| As at 31st March, 2022 (A-B) | 2.25 | |
| As at 31st March, 2022 (A-B) As at 31st March, 2023 (C-D) | 0.07 | 0.07 |
| As at 315t Maion, 2023 (C-D) | ·• | - |





Annexure VI Notes to Restated Consolidated Financial Information

| (All amounts in | million. | unlece | otherwise | etated) |
|-----------------|----------|--------|-----------|---------|

| Pledged with bank for bank guarantees | 8.49 11.07 19.56 | 9.91 12.34 22.25 | 2.24 13.71 15.94 |
|---------------------------------------|--------------------------------------------|----------------------------------------------|-----------------------------------------------------------------------------|
| Pledged with bank for bank guarantees | 11.07 19.56 | 12.34 | 13.71 |
| Pledged with bank for bank guarantees | 11.07 19.56 | 12.34 | 13.71 |
| Pledged with bank for bank guarantees | 11.07 19.56 | 12.34 | 13.71 |
| 2 seeges war out for out gustuitees | 19.56 | | |
| | | | |
| | | | |
| | | | |
| | 9.41 | 40.55 | 7.84 |
| | - | 17.90 | 62.59 |
| 8 | 9.41 | 58.45 | 70.44 |
| | | | |
| | | | |
| | | | |
| | 42.23 | 41.67 | 20.67 |
| | 18.47 | 10.28 | 13.23 |
| | 60.70 | 51.95 | 33.90 |
| | | | |
| | ÷ | | |
| d | | | |
| - | - | - | - |
| red | | | |
| | | | |
| | 1 1/19 21 | 012.22 | 387.88 |
| | | | 387.88 |
| | | | 20.23 |
| | | = | 367.65 |
| | 2,5.311 | | 507.05 |
| rease in Credit Risk-Doubtful | _ | | A1 |
| | 1,076.44 | - | - |
| | d ired rease in Credit Risk-Doubtful | 60.70 d - 1,148.21 1,148.21 71.76 1,076.44 | 60.70 51.95 d 1,148.21 912.22 1,148.21 912.22 71.76 56.84 1,076.44 855.38 |

Trade receivables are unsecured and are derived from revenue earned from providing medical, healtcare and other ancillary services. No interest is charged on the outstanding balance, regardless of the age of the balance. The group applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss towards expected risk of delays and default in collection.

The group has used a practical expedient by computing the expected credit loss allowance based on recovery pattern of receivables in the past. Management makes specific provision in cases where there are known specific risks of customer default in making repayments. The provision matrix takes into account historical credit loss experience and adjusted for forward-looking information.





Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Trade Receivable aging schedule As at 31st March, 2023

| Particulars | Outstanding for following periods | | | | | | |
|------------------------------------------------------|-----------------------------------|-----------------|-----------|-----------|-------------------|----------|--|
| | Less than 6 months | 6 Months-1 year | 1-2 years | 2-3 years | More than 3 years | Total | |
| a) Undisputed Trade receivables- Considered Good | 882.85 | 220.04 | 45.30 | 0.01 | • | 1,148.21 | |
| b) Undisputed Trade receivables- Considered Doubtful | - | - | - | - | | · · | |
| c) Undisputed Trade receivables- Credit Impaired | - | | - | - | - | - | |
| d) Disputed Trade receivables- Considered Good | | _ | - | - | | - | |
| e) Disputed Trade receivables- Considered Doubtful | - | | _ | - | | | |
| f) Disputed Trade receivables- Credit Impaired | - | - | - | - | | - | |

As at 31st March, 2022

| Particulars | Outstanding for following periods | | | | | | |
|------------------------------------------------------|-----------------------------------|-----------------|--------------|-----------|-------------------|--------|--|
| | Less than 6 months | 6 Months-1 year | 1-2 years | 2-3 years | More than 3 years | Total | |
| a) Undisputed Trade receivables- Considered Good | 680.04 | 230.97 | 1.22 | - | | 912.22 | |
| b) Undisputed Trade receivables- Considered Doubtful | | - | - | - | | - | |
| c) Undisputed Trade receivables- Credit Impaired | - | - | 5 - 5 | _ | - | - | |
| d) Disputed Trade receivables- Considered Good | - | | - | - | | - | |
| e) Disputed Trade receivables- Considered Doubtful | - | - | | - | | - | |
| f) Disputed Trade receivables- Credit Impaired | | | - | _ | | - | |

As at 31st March, 2021

| Particulars | | Outstanding for following periods | | | | | | |
|------------------------------------------------------|--------------------|-----------------------------------|-----------|-----------|-------------------|--------|--|--|
| | Less than 6 months | 6 Months-1 year | 1-2 years | 2-3 years | More than 3 years | Total | | |
| a) Undisputed Trade receivables- Considered Good | 368.53 | 19.36 | - | - | | 387.88 | | |
| b) Undisputed Trade receivables- Considered Doubtful | - | | - | - | | - | | |
| c) Undisputed Trade receivables- Credit Impaired | - | - | :-: | - | - | - | | |
| d) Disputed Trade receivables- Considered Good | - | - | - | - | | - | | |
| e) Disputed Trade receivables- Considered Doubtful | - | | - | - | | - | | |
| f) Disputed Trade receivables- Credit Impaired | | - | - | - | - | - | | |





Annexure VI Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

| Note | Particulars | As at March 31, | As at March 31, | As at March 31, |
|------|------------------------------------------------------------------|-----------------|-----------------|-----------------|
| No. | | 2023 | 2022 | 2021 |
| 8 | Cash and Cash Equivalants | | | |
| | Balance with banks in current accounts | 27.21 | | |
| | | 354.24 | 111.52 | 44.07 |
| | UPI & Other Amount Recoverable | 2.56 | 2.12 | 1.75 |
| | Cash in hand | 15.45 | 2.93 | 4.18 |
| | Bank Deposits with maturing with in 3 months- pledged with banks | 2.08 | 0.51 | - |
| | Total | 374.32 | 117.07 | 50.00 |
| 9 | Bank balances other than cash and cash equivalents | | | |
| | Bank Deposits & Interest accured on Bank deposit | 10.11 | 3.74 | 1.52 |
| | Total | 10.11 | 3.74 | 1.52 |
| 10 | Current Tax Assets | | / | |
| | TDS & Advance income tax (net of provision for income tax) | 111.78 | 30.23 | 18.06 |
| | Total | 111.78 | 30.23 | 18.06 |
| | | | | |
| 11 | Other Current Assets | | | |
| | Staff Imprest and Advances | 1.62 | 4.27 | 7.22 |
| | Other amount recoverable | 59.23 | 8.67 | 14.03 |
| | Unamortised capital issue expenses | 63.04 | 21.41 | = .100 |
| | Security Deposit-others | 5.43 | 1.28 | 0.84 |
| | Total | 129.31 | 35.63 | 22.09 |

^{*} The Parent Company has incurred expenses towards various services received in connection with the proposed issue of fresh equity shares by the Company and the sale of equity shares by the existing shareholders by the way of Offer for Sale.





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

| | | As at March 31, | As at March 31, | As at March 31, |
|-----|---------------------------------------------------------------------------------------------------------------|----------------------|-----------------|-----------------|
| 12 | Share Capital | 2023 | 2022 | 2021 |
| | Authorised 115,000,000 (Previous Year 115,000,000 & 20,000,000 Equity shares in 2021) of Rs. 10/- each | 1,150.00 | 1,150.00 | 200.00 |
| | Total | 1,150.00 | 1,150.00 | 200.00 |
| | Equity share capital | | | |
| | Issued, Subscribed & Paid up | | | |
| | 65,516,900 (Previous Year 65,516,900 & 16,379,225 Equity shares in 2021) of Rs. | 655.17 | 655.17 | 163.79 |
| | 10/- each | | | 102.73 |
| | Issued, Subscribed & Not Paid up | | | |
| | NIL | - | 1 | - |
| | Total | 655.17 | 655.17 | 163.79 |
| 2.1 | Reconciliation of number of shares outstanding at the beginning and at the end Equity Shares | of the reporting per | iod | |
| | Number of Shares outstanding at the beginning of the year | 65,516,900 | 16,379,225 | 16,379,225 |
| | Number of Shares issued during the year in cash | | - | 10,077,220 |
| | Number of Shares issued during the year other than in cash | - | . 49,137,675 | - |
| | Number of Shares brought back during the year | - | - | - |
| | Shares outstanding at the end of the year | 65,516,900 | 65,516,900 | 16,379,225 |

12.2 Terms / rights attached to Equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of equity shares is entitled to one vote per share.

In the event of the liquidation of the Company, the holder of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

12.3 Equity Shares in the company held by each shareholder holding more than 5 percent shares specifying the number of shares held

| Name of Shareholder | As at Mai | ch 31, 2023 | As at March | h 31, 2022 |
|----------------------|---------------------------|--------------|---------------------------|--------------|
| | No. of equity shares held | % of holding | No. of equity shares held | % of holding |
| Dr. Ajay Kumar Tyagi | 27,021,600 | 41.24% | 27,021,600 | 41.24% |
| Dr. Kapil Kumar | 12,164,400 | 18.57% | 12,164,400 | 18.57% |
| Dr. Manju Tyagi | 11,524,200 | 17.59% | 11,524,200 | 17.59% |
| Dr. Neena Tyagi | 7,019,600 | 10.71% | 7,019,600 | 10.71% |
| Vimla Tyagi | 3,743,000 | 5.71% | 3,743,000 | 5.71% |
| | As at Mar | ch 31, 2021 | | |
| Name of Shareholder | No. of equity shares held | % of holding | 2 | |
| Dr. Ajay Kumar Tyagi | 6,755,400 | 41.24% | | |
| Dr. Kapil Kumar | 3,041,100 | 18.57% | | |
| Dr. Manju Tyagi | 2,881,050 | 17.59% | | |
| Dr. Neena Tyagi | 1,754,900 | 10.71% | | |
| Vimla Tyagi | 935,750 | 5.71% | | |

12.4 Equity shares reserved for issue under options and contracts / commitments for the sale of shares / disinvestments, including terms and amounts NIL





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

12.5 Aggregate number and class of equity shares allotted as fully paid up pursuant to contract without payment being received in cash, allotment by way of bonus shares or shares bought back

| Particulars | 2022-23 | 2021-22 | 2020-21 | 2019-20 | 2018-19 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|------------|---------|---------|---------|
| Company has allotted 49.14 million equity shares of Rs. 10 each, valued at Rs. 491.38 million on to existing shareholders by way of capitalisation of Share premium and accumulated Profit & Loss during FY 2021-22 | - | 49,137,675 | - | - | 3 |

12.6 The company does not have any holding company or ultimate holding company.

12.7 Shareholding of Promoters

S. No. Name of Shareholder

As at March 31, 2023

As at March 31, 2022

| | | No. of equity shares held | % of total shares | % Change during Year | No. of equity shares held | % of total shares | % Change during Year |
|---|----------------------------|---------------------------|-------------------|-------------------------|---------------------------|-------------------|-------------------------|
| 1 | Dr. Ajay Kumar Tyagi | | | | | | |
| | Opening Balance | 27,021,600 | 41.24% | | 6,755,400 | 41.24% | |
| | Acquired During the year * | - | | | 20,266,200 | 30.93% | |
| | Closing Balance | 27,021,600 | 41.24% | - | 27,021,600 | 41.24% | 300.00% |
| 2 | Dr. Kapil Kumar | | | | | | |
| | Opening Balance | 12,164,400 | 18.57% | | 3,041,100 | 18.57% | |
| | Acquired During the year * | | | | 9,123,300 | 13.93% | |
| | Closing Balance | 12,164,400 | 18.57% | - | 12,164,400 | 18.57% | 300.00% |

^{*} Acquired by the way of Bonus shares issued by the Company

S. No. Name of Shareholder

As at March 31, 2021

| | | No. of equity shares held | % of total shares | % Change during Year |
|---|--------------------------|---------------------------|-------------------|----------------------|
| 1 | Dr. Ajay Kumar Tyagi | | | |
| | Opening Balance | 6,755,400 | 41.24% | |
| | Acquired During the year | - | - | |
| | Closing Balance | 6,755,400 | 41.24% | 0.00% |
| 2 | Dr. Kapil Kumar | | | |
| | Opening Balance | 3,041,100 | 18.57% | |
| | Acquired During the year | - | - | |
| | Closing Balance | 3,041,100 | 18.57% | 0.00% |





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

13 Other Equity

| Particulars | Securities Premium | Retained Earnings | Other Comprehensive Income | Equity attributable to shareholders of the company |
|-------------------------------------------------------------------------|-----------------------|-------------------|----------------------------------|----------------------------------------------------------|
| Balance as at 1st April, 2020 | 176.6 | 0 202.53 | 0.00 | 379.14 |
| Surplus in the statement of profit and loss transferred during the year | - | 181.60 | | 181.60 |
| Remeasurement of defined benefit liability (net of tax) | | | 0.02 | 0.02 |
| | - | - | | - |
| Balance as at 31st March, 2021 | 176.6 | 0 384.13 | 0.02 | 560.76 |

| Particulars | Securities Premium | Retained Earnings | Other Comprehensive Income | Equity attributable to shareholders of the company |
|-------------------------------------------------------------------------|-----------------------|-------------------|----------------------------------|----------------------------------------------------------|
| Balance as at 1st April, 2021 | 176. | 60 384.13 | 0.02 | 560.76 |
| Surplus in the statement of profit and loss transferred during the year | - | 441.62 | - | 441.62 |
| Issue of Bonus Shares | (176. | 60) (314.77) | | (491.38) |
| Remeasurement of defined benefit liability (net of tax) | | - | 2.67 | 2.67 |
| Balance as at 31st March, 2022 | - | 510.98 | 2.70 | 513.68 |

| Particulars | Securities Premium | Retained Earnings | Other Comprehensive Income | Equity attributable to shareholders of the company |
|-------------------------------------------------------------------------|-----------------------|-------------------|----------------------------------|----------------------------------------------------------|
| Balance as at 1st April, 2022 | | - 510.98 | 2,70 | 513.68 |
| Surplus in the statement of profit and loss transferred during the year | 3 | - 657.68 | _ | 657.68 |
| Issue of Bonus Shares | 0 | | - | - |
| Remeasurement of defined benefit liability (net of tax) | 3 | | 3.11 | 3.11 |
| Balance as at 31st March, 2023 | | 1,168.66 | 5.81 | 1,174.47 |

Securities Premium

Securities premium is used to record the premium received on issue of shares. It is utilised in accordance with the provisions of the Companies Act, 2013.

Retained Earnings

The amount that can be distributed by the company as dividends to pay its equity and preference (if any) shareholders.

Other Comprehensive Income

Remeasurement of defined benefit plans comprise of acturial gains and losses.





Annexure VI Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

| Note | Particulars | | As at March 31, | |
|------|---------------------------------------------------------------------------|--------------|-----------------|----------|
| No. | n' | 2023 | 2022 | 2021 |
| 14 | Borrowings | | | |
| | Secured | | | |
| | Term loans (Indian currency) | | | |
| | From banks | 2,373.59 | 2,325.60 | 817.20 |
| | From financial institutions | 82.83 | 78.17 | 979.50 |
| | Less: Current Maturities[refer note no. 17] | 463.26 | 348.91 | 178.78 |
| | | 1,993.16 | 2,054.86 | 1,617.98 |
| | Loan for Vehicles against hypothecation - Banks | 12.78 | 18.96 | 16.72 |
| | Toward. | | | |
| | Unsecured From banks | | | |
| | From financial institutions | ž | - | 0.83 |
| | From linancial institutions | | · • | 1.65 |
| 30 | Total | 2,005.94 | 2,073.82 | 1,637.18 |
| 23 | For terms and conditions, security and repayments please refer note no 35 | | _, | 2,007.20 |
| 15 | Provisions | | | |
| | Provision for employee benefit | 12.99 | 9.78 | 0.41 |
| | Total | 12.99 | 9.78 | 0.41 |
| 16 | Deferred Tax Liabilities-Net | | | |
| | Deferred tax liabilities | | | |
| | On account of Depreciation | 88.54 | 91.73 | 78.57 |
| | On account of Others | 0.52 | 1.29 | 1.62 |
| | | | | |
| | Sub Total (A) | 89.05 | 93.01 | 80.19 |
| | Deferred tax Assets | | | |
| | On account of Losses and Tax disallowances | 144.79 | 112.33 | 3.00 |
| | On account of Others | 22.18 | 19.30 | 4.76 |
| | MAT credit entitlement | 4.87 | 15.90 | 33.92 |
| | Sub Total (B) | 171.85 | 147.54 | 41.68 |
| 1 | Deferred Tax Liabilities-Net (A-B) | (82.79) | (54.53) | 38.52 |
| 1 | For movement of deferred Tax, refer Note 16.1 | 10. | | |





Annexure VI
Notes to Restated Consolidated Financial Information
(All amounts in million, unless otherwise stated)

Note No. 16.1

Deferred Tax Assets/Deferred Tax Liabilities

As on 31st March, 2021

| Particulars | Opening balance | Recognised in Profit or loss | Acquired during the year | Other Comprehensive Income | Closing balance |
|---------------------------------------------------------------------|-----------------|---------------------------------|---------------------------------------|-------------------------------|-----------------|
| Deferred tax assets in relation to: | | | · · · · · · · · · · · · · · · · · · · | Ancome | |
| MAT Credit | 17.29 | 16.63 | _ | 120 | 33.92 |
| Provision for employee benefits | 0.10 | 0.03 | 12 | (0.01) | 0.13 |
| Business loss & Tax disallowance benefit carried forward and others | 24.48 | (21.61) | - | (0.01) | 2.87 |
| On IND AS Adjustments | 4.62 | 0.15 | | - | 4.76 |
| Deferred Tax Assets Total | 46.49 | (4.81) | - | (0.01) | 41.68 |
| Deferred tax liabilities on account of | | | | | |
| Due to depreciation | 47.41 | 31.16 | 1-1 | - | 78.57 |
| Others | 2.61 | (0.99) | - | | 1.62 |
| Deferred Tax Liabilities Total | 50.02 | 30.17 | - | - | 80,19 |
| Deferred Tax Assets/(Liability) | (3.53) | (34.98) | - | (0.01) | (38.52 |

As on 31st March, 2022

| Particulars | Opening balance | Recognised in Profit or loss | Acquired during the year | Other Comprehensive Income | Closing balance |
|---------------------------------------------------------------------|-----------------|---------------------------------|-----------------------------|-------------------------------|-----------------|
| Deferred tax assets in relation to: | | | , | | |
| MAT Credit | 33.92 | (18.02) | <u>-</u> , | | 15.90 |
| Provision for employee benefits | 0.13 | 3.80 | - 2 | (1.10) | 2.83 |
| Business loss & Tax disallowance benefit carried forward and others | 2.87 | 0.11 | 109.35 | , | 112.33 |
| On IND AS Adjustments | 4.76 | 11.71 | - | _ | 16.47 |
| Deferred Tax Assets Total | 41.68 | (2.39) | 109,35 | (1.10) | 147.54 |
| Deferred tax liabilities on account of | | | | | |
| Due to depreciation | 78.57 | 7.29 | 5.87 | | 91.73 |
| Others | 1.62 | (0.34) | | | 1.29 |
| Deferred Tax Liabilities Total | 80.19 | 6.95 | 5.87 | | 93.01 |
| Deferred Tax Assets/(Liability) | (38.52) | (9.34) | 103.48 | (1.10) | 54.53 |

As on 31st March, 2023

| Particulars | Opening balance | Recognised in Profit or loss | Acquired during the year | Other Comprehensive Income | Closing balance |
|---------------------------------------------------------------------|-----------------|---------------------------------|-----------------------------|-------------------------------|-----------------|
| Deferred tax assets in relation to: | | | | | |
| MAT Credit | 15,90 | (11.03) | | | 4.87 |
| Provision for employee benefits | 2.83 | 1.62 | - | (0.90) | 3,55 |
| Business loss & Tax disallowance benefit carried forward and others | 112.33 | 32.46 | | () | 144.79 |
| On IND AS Adjustments | 16.47 | 2.16 | - | | 18.63 |
| Deferred Tax Assets Total | 147.54 | 25.20 | 0.70 | (0.90) | 171.85 |
| Deferred tax liabilities on account of | | | | | |
| Due to depreciation | 91.73 | (3.19) | | | 88.54 |
| Others | 1.29 | (0.77) | - | | 0.52 |
| Deferred Tax Liabilities Total | 93.01 | (3.96) | | - | 89.05 |
| Deferred Tax Assets/(Liability) | 54,53 | 29.16 | - | (0.90) | 82.79 |





Annexure VI

Notes to Restated Consolidated Financial Information

| Note | | As at March 31, | As at March 31, | As at March 31, | | | | | |
|------|--------------------------------------------------------|----------------------------------------------------------------------------|-----------------|-----------------|--|--|--|--|--|
| No. | Particulars | 2023 | 2022 | 2021 | | | | | |
| . 17 | Borrowings* | | | | | | | | |
| | Secured | | | | | | | | |
| | Working Capital from Banks | 162.94 | 100.46 | 35.49 | | | | | |
| | Current maturities of Long Term Borrowings | | | 20.1. | | | | | |
| | From banks | 431.75 | 322.44 | 113.9 | | | | | |
| | From financial institutions | 31.51 | 26.47 | 64.80 | | | | | |
| | Loan for Vehicles against hypothecation- Banks | 5.61 | 7.05 | 6.1: | | | | | |
| | Unsecured | | | | | | | | |
| | From banks | - | _ | 2.40 | | | | | |
| | From financial institutions | | | 1.12 | | | | | |
| | From Directors | - | 51.64 | - | | | | | |
| | | 631.82 | 508.06 | 223.91 | | | | | |
| | *For terms and conditions, security and repayments ple | *For terms and conditions, security and repayments please refer note no 35 | | | | | | | |
| 18 | Trade payables (refer note no. 33) | | | | | | | | |
| | (a) Due to Micro and small enterprises | 15.08 | 22.81 | | | | | | |
| | (b) Due to others | 153.69 | 181.31 | 165.33 | | | | | |
| | Total | 168.78 | 204.12 | 165,33 | | | | | |

Trade Payables Ageing Schedule

As at 31st March, 2023

| Particulars | Less than 1 year | 1-2 Years | 2-3 Years | More than 3 Years | Total |
|-------------------------|------------------|-----------|-----------|-------------------|--------|
| a) MSME | 15.08 | - | - | - | 15.08 |
| b) Others | 153.69 | - | - | 2 | 153.69 |
| c) Disputed dues- MSME | - | - | | | - |
| d) Disputed dues-Others | - | _ | - | - | _ |
| Total | 168.78 | - | - | - | 168,78 |

As at 31st March, 2022

| 110 111 0 101 1 1 1 1 1 1 1 1 1 1 1 1 1 | | | | | |
|-----------------------------------------|------------------|-----------|-----------|-------------------|--------|
| Particulars | Less than 1 year | 1-2 Years | 2-3 Years | More than 3 Years | Total |
| a) MSME | 22.81 | - | - | | 22.81 |
| b) Others | 181.31 | - | - | - | 181.31 |
| c) Disputed dues- MSME | - | - | - | - | - |
| d) Disputed dues- Others | - | - | _ | - | - |
| Total | 204.12 | - | | - | 204.12 |

As at 31st March, 2021

| Particulars Particulars | Less than 1 year | 1-2 Years | 2-3 Year | s M | lore than 3 Years | Total |
|--------------------------|------------------|-----------|----------|-----|-------------------|--------|
| a) MSME | • | - | × | - | n | |
| b) Others | 165.33 | - | | - | - | 165.33 |
| c) Disputed dues- MSME | -1 | - | | - | - | - |
| d) Disputed dues- Others | - | - | | - | 127 | = |
| Total | 165.33 | | | - | - | 165.33 |





Annexure VI Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

| | | As at March 31, A | s at March 31, A | s at March 31 |
|---------|---------------------------------------------|----------------------|----------------------|-----------------------|
| Note No | Particulars | 2023 | 2022 | 2021 |
| 19 | Other Financial Liabilities | | | |
| | Liability for land | _ | _ | 11.91 |
| | Interest accrued but not due | 1.13 | 0.73 | - |
| | Expenses Payable | 141.27 | 144.63 | 95.29 |
| | Total | 142.40 | 145.36 | 107.20 |
| 20 | Other Current Liabilities | 90010 | 25.22 | ••• |
| | Statutory Dues Other Liabilities | 26.46 | 25.33 | 29.98 |
| | Advances from customer | - | 0.56 | - |
| | Total | 4.69 31.15 | 6.39 32.28 | 5.27 35.2 5 |
| 21 | Provisions | | | |
| | Provision for employee benefit | 0.59 | 0.05 | 0.06 |
| | Provision for taxation - Net of Advance Tax | | 62.06 | - |
| | Total | 0.59 | 62.10 | 0.06 |





Annexure VI
Notes to Restated Consolidated Financial Information
(All amounts in million, unless otherwise stated)

| Note No. | Particulars | Year ended | Year ended | Year ended |
|-------------|-------------------------------------------------------------------|---------------|---------------|-----------------|
| 22 | Revenue from operations | 31-March-2023 | 31-March-2022 | 31-March-2021 |
| ta ta | Acvenue from operations | | | |
| | Income from medical and healthcare services* | 5 202 02 | 4 000 25 | |
| | | 5,202.93 | 4,009.37 | 2,286.74 |
| | Total | 5,202.93 | 4,009.37 | 2,286.74 |
| | *Refer Note 34 | | 1,002107 | 2,200.7 |
| 22 | 04 | | | |
| 23 | Other income | | | |
| | Interest income on bank deposits Interest on income tax refund | 1.41 | 1.02 | 0.37 |
| | Other incomes- Sale of Food & Beverages | 2.86 | 5.38 | 4.15 |
| | Rental Income from telecom towers | 21.96 | 9.34 | |
| | Interest income - INDAS | 0.89 | 0.75 | 0.63 |
| | Rental Income from Ambulance | 0.01 0.94 | 0.00 | - |
| | Total | 28.07 | 16,49 | F 15 |
| | | 20,07 | 10,49 | 5.15 |
| 24 | Cost of Material Consumed | | | |
| | W. H. L. | | | |
| | Medicines consumed | | | |
| | Opening balance Purchase | 41.67 | 20.67 | 18.58 |
| | Less: closing stock | 444.21 | 521.20 | 336.56 |
| | Material Consumed-A | (42.23) | (41.67) | (20.67 |
| | | 443.66 | 500.19 | 334.47 |
| | Consumable stores | | | |
| | Opening balance | 10.28 | 13.23 | 10.00 |
| | Purchase | 493.88 | 310.14 | 10.02 131.93 |
| | Less: closing stock | (18.47) | (10.28) | (13.23) |
| | Stores Consumed-B | 485.69 | 313.09 | 128.72 |
| | TOTAL COST OF MATERIAL CONSUMED A+B | 929.35 | 813.28 | 463.18 |
| | | 7117103 | 613.26 | 403.16 |
| 25 | Employee benefits expense | | | |
| | Salaries, wages and other benefits | 848.72 | 737.77 | 424.40 |
| | Director's Remuneration | 60.00 | 55.00 | 434.49 28.80 |
| | Key men insurance | 1.34 | 1.48 | 1.41 |
| | Staff welfare expenses | 9.24 | 10.43 | 2.17 |
| _ | Total | 919.30 | 804.68 | 466.88 |
| | | | | |
| 6 | Finance cost | | | |
| 1 | interest on secured loans | 203.80 | 190.46 | 175.14 |
| I | nterest expense on Lease Liability | 2.21 | 2.98 | 10.56 |
| I | nterest on unsecured loans | | 0.57 | 1.94 |
| | nterest on others | 0.13 | 13.47 | - |
| | nterest on Others-MSME | 0.13 | 0.18 | - |
| I | nterest on Statutory Dues | 7.61 | 7.20 | 0.79 |
| 7 | otal | 213.87 | 214.86 | 188.44 |
| 7 I | Depreciation and amortization expenses | | #1100 | 100,44 |
| | | | | |
| | Depreciation on Property, Plant & Equipment and Intangible Assets | 254.07 | 257.93 | 185.01 |
| Γ | Depreciation on Leased Assets | 21.00 | 20.76 | 20.58 |
| T | otal | Wateramana | | |
| _ | V394 | 275.07 | 278.68 | 205.60 |





Annexure VI Notes to Restated Consolidated Financial Information

| | nts in million, unless otherwise stated) | | | |
|-------------|------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|
| Note No. | Particulars | Year ended 31-March-2023 | Year ended 31-March-2022 | Year ended 31-March-2021 |
| 28 | Other expenses | | | |
| | Specialist Charges | 930.91 | 510.22 | 289.98 |
| | Lab Expenses | 50.10 | 37.17 | |
| | Power, Fuel & Utilities | 137.11 | 121.88 | 36.14 93.26 |
| | Advertisement & Marketing | 43.99 | 10.96 | 4.67 |
| | Vehicle running & maintenance | 27.69 | 25.70 | |
| | Repair & maintenance | 179.63 | 87.50 | 10.32 43.90 |
| | Discount allowed | 426.17 | 260,55 | |
| | Provision for Expected credit loss | 14.93 | 36.60 | 134.19 |
| | Bank & Finance Charge | 13.96 | 11.61 | 3.56 |
| | Filling Fees | | | 10.46 |
| | Legal & Professional Charges | 0.05 12.39 | 8.61 | - |
| | Canteen & food | | 1.95 | - 10.51 |
| | CSR Expenses | 43.57 | 50.77 | 18.51 |
| | Conveyance & travel | 6.70 | 3.00 | 1.10 |
| | - | 27.57 | 12.89 | 2.62 |
| | Director's Sitting Fees Rent | 0.93 | 0.42 | |
| | | 19.39 | 18.50 | 9.39 |
| | Printing & stationery | 2.51 | 8.24 | 5.35 |
| | Office expenses | 53.87 | 49.94 | 10.74 |
| | Communication Exp | 3.85 | 5.08 | 3.42 |
| | Insurance expenses | 3.45 | 0.72 | 1.34 |
| | Auditor's remuneration | | | |
| | - For Audit fees | 1.12 | 0.73 | 0.11 |
| | Other Miscellaneous Expenses | 16.75 | 20.22 | 7.52 |
| | Total | 2,016.63 | 1,283.29 | 686.56 |
| 29 | Earning per Share | | | |
| 4) | Profit for the period/year attributable to owners of the company | 660.79 | 444.30 | 181.60 |
| | Shares | | 11.11.00 | 101.00 |
| | | | | |
| | Weighted Average number of equity shares at the beginning of the | (5.51 (000 | C# #4 C 000 | 46000000 |
| | period/year | 65,516,900 | 65,516,900 | 16,379,225 |
| 4.3.1 | Weighted Average number of equity shares issued during the | | • | |
| Add | period/year | • | ~ | - |
| | Weighted Average number of equity shares at the end of the | | | 79.000.000 |
| | period/year | 65,516,900 | 65,516,900 | 16,379,225 |
| Add/ | Bonus shares issued subsequent to period end considered for | 1.7 | | |
| Less) | calculation of Earning per share for relevant periods. | SHY | | 49,137,675 |
| (Less) | calculation of Latining per share for relevant periods. | 65,516,900 | 65,516,900 | |
| Add/ | | 03,310,900 | 05,510,900 | 65,516,900 |
| | Items having dilutive impact on equity shares | ~ | - | |
| | Weighted Average number of equity shares (without bonus shares) | | | |
| | at the end of the year-Diluted EPS | 65,516,900 | 65,516,900 | 16,379,225 |
| | Equality Por Chara Da | 40.00 | | 44.00 |
| | Earnings Per Share- Rs | 10.09 | 6.78 | 11.09 |
| | Diluted Earnings Per Share- Rs | 10.09 | 6.78 | 11.09 |
| | Weighted Average number of equity shares (with bonus shares) at | | | |
| | the end of the year-Diluted EPS | 65,516,900 | 65,516,900 | 65,516,900 |
| | Earnings Per Share- Rs | 10.09 | 6.78 | 2.77 |
| | | 10.07 | 0.70 | 2.11 |
| | Diluted Earnings Per Share- Rs | 10.09 | 6.78 | 2.77 |
| | | | | |





Annexure VI

Notes to Restated Consolidated Financial Information (All amounts in million, unless otherwise stated)

30 Right of Use Assets

A. Transition to Ind AS 116 "Leases"

A new lease standard i.e., Ind AS 116 has been notified to be effective w.e.f. 1 April 2019 which provide guidelines for the accounting of the lease contracts entered in the capacity of a lessee and a lessor. For the purpose of preparation of Restated Standalone Financial Information, the management has evaluated the impact of change in accounting policies on adoption of Ind AS 116 for the year ended 31 March 2019. Hence in these Restated Standalone Financial Information, Ind AS 116 has been adopted with effect from April 1, 2018 following modified retrospective method (i.e. on 1 April 2018 the company has measured the lease liability at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate and a right-of-use assets are measured at their carrying amount as if Ind AS 116 has been applied since the commencement date, discounted using the lessee's incremental borrowing rate at the date of initial application). Ind AS 116 supersedes Ind AS 17 Leases including its appendices (Appendix C of Ind AS 17 Determining whether an Arrangement contains a Lease, Appendix A of Ind AS 17 Operating Leases- Incentives and Appendix B of Ind AS 17 Evaluating the Substance of Transactions Involving the Legal Form of a Lease). The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to recognise most leases on the balance sheet. Following are the changes in the carrying values of right of use assets for the year ended March 31, 2023, 31 March 2022 & 31 March 2021:

The company has elected not to apply the requirements of Ind AS 116 "Leases" to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term except inflation adjustment.

B. Following are the changes in the carrying values of right of use assets

| Following are the changes Particulars | Category of ROU Assets- Medical Equiptments | Category of ROU Assets- Office | Total |
|------------------------------------------------|------------------------------------------------|-----------------------------------|--------|
| Gross Block | 1-1-1-1-1 | 110010 011100 | |
| Balance as at March 31, 2020 | 123.57 | | 123,57 |
| Additions | | | 120.57 |
| Deletion | 2 | | |
| Balance as at March 31, 2021A | 123.57 | | 123,57 |
| Additions | - | 1.24 | 1.24 |
| Deletion | - | 1.24 | 1.24 |
| Balance as at March 31, 2022-B | 123.57 | 1.24 | 124.81 |
| Additions | - | | 124.01 |
| Deletion | - | | - |
| Balance as at March 31, 2023—C | 123.57 | 1.24 | 124.81 |
| Accumulated Depreciation | | | |
| Accmulated Depreciation as at March 31, 2020 | 27.35 | 2 | 27.35 |
| Depreciation charge for the year | 20.58 | | 20.58 |
| Disposals | 1=1 | _ | |
| Accmulated Depreciation as at March 31, 2021D | 47.94 | _ | 47.94 |
| Depreciation charge for the year | 20.58 | 0.17 | 20.76 |
| Disposals | | | - |
| Accmulated Depreciation as at March 31, 2022E | 68.52 | 0.17 | 68.69 |
| Depreciation charge for the year | 20.58 | 0.41 | 21.00 |
| Disposals | | • | 21.00 |
| Accmulated Depreciation as at March 31, 2023 F | 89.11 | 0.59 | 89.69 |
| Net Carrying amounts | | | |
| As at March 31, 2021 (A-D) | 75.63 | | 75.63 |
| As at March 31, 2022 (B-E) | 55.04 | 1.07 | 56.12 |
| As at March 31, 2023 (C-F) | 34.46 | 0.66 | 35.12 |
| 70 U.St. 52 | 21.10 | 0.00 | 33.12 |

The aggregate depreciation expense on ROU assets is included under depreciation and amortization expense in the statement of Profit and Loss.

C. The following is the rental expense recorded for short-term leases, variable leases and low value assets

| Particulars | For the | For the | For the |
|------------------|----------------|---------------|---------------|
| | year ended | year ended | year ended |
| | March 31, 2023 | 31 March 2022 | 31 March 2021 |
| Short Term Lease | 19 39 | 18 50 | 0.30 |





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

D. Following is the movement in lease liabilities for the year ended March 31, 2023

| Particulars | Lease liabilities |
|-------------------------------|-------------------|
| Balance as at 1 April 2020 | 90.46 |
| Additions | - |
| Finance cost | 3.80 |
| Payment of lease liabilities | 21.24 |
| Balance as at 31 March 2021 | 73.02 |
| Non-current lease liabilities | 54.76 |
| Current lease liabilities | 18.26 |
| Balance as at 1 April 2021 | 73.02 |
| Additions | 1.24 |
| Finance cost | 3.02 |
| Payment of lease liabilities | 21.43 |
| Balance as at 31 March 2022 | 55,85 |
| Non-current lease liabilities | 36.74 |
| Current lease liabilities | 19.12 |
| Balance as at 1 April 2022 | a |
| Additions | 55.85 |
| Finance cost | • |
| | 2.21 |
| Payment of lease liabilities | 21.70 |
| Balance as at March 31, 2023 | 36.36 |
| Non-current lease liabilities | 15.91 |
| Current lease liabilities | 20.45 |

E. The following is the cash outflow on leases during the periods/years:

| Particulars | For the year ended March 31, 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|------------------------------|-----------------------------------------|----------------------------------------|----------------------------------------|
| Payment of lease liabilities | 21.70 | 21.43 | 21.24 |
| Short-term lease expense | 19.39 | 18.50 | 9.39 |
| Total cash outflow on leases | 41.09 | 39.93 | 30.62 |

F. The table below provides details regarding the contractual maturities of lease liabilities as at period/year-end on an undiscounted basis:

| Particulars | For the year ended March 31, 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|-----------------------------------|-----------------------------------------|----------------------------------------|----------------------------------------|
| Less than 1 year | 28.37 | 28.80 | 26.75 |
| 1 to 5 years More than 5 years | 16.69 | 37.95 | 80.47 |

The company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.





Annexure VI
Notes to Restated Consolidated Financial Information
(All amounts in million, unless otherwise stated)

Note 31 (i): Fair Value Measurement Categories of financial instruments

| Financial assets | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
|--------------------------------------------------|-------------------------|-------------------------|-------------------------|
| Measured at amortised cost | | | |
| (i) Trade receivables | 1,076.44 | 855.38 | 367.65 |
| (ii) Cash and Bank balance | 374.32 | 117.07 | 50.00 |
| (iii) Other Bank Balances | 10.11 | 3.74 | 1.52 |
| (iv) Other financial assets-non current | 19.56 | 22.25 | 15.94 |
| | 1,480.45 | 998.44 | 435.11 |
| Measured at Fair value | 1,100.13 | JJ0.44 | 433.11 |
| Investment other than investment in subsidiaries | | - | |
| Financial liabilities | As at March 31, | As at March 31, | As at March 31, |
| | 2023 | 2022 | 2021 |
| Measured at amortised cost | | | |
| (i) Borrowings | 2,637.76 | 2,581.88 | 1,861.09 |
| (ii) Other financial liabilities | 142.40 | 145.36 | 107.20 |
| (iii) Lease Liabilities | 36.36 | 55.85 | 73.02 |
| (iv) Trade and other payables | 168.78 | 204.12 | 165.33 |
| Total | 2,985.29 | 2,987.22 | 2,206.65 |

(i) Fair Value Hierarchy

Fair value measurements

| Particulars | | Fair value as at | | | | |
|-----------------------|-------------------------|-------------------------|-------------------------|--|--|--|
| " | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 | | | |
| Financial assets | 4 | - | | | | |
| Financial Liabilities | | | | | | |

The fair values of current debtors, cash & bank balances, loan to related party, security deposit to government department, current creditors and current borrowings and other financial liability are assumed to approximate their carrying amounts due to the short-term maturities of these assets and liabilities.

| | # | Carrying value | |
|-------------------------------------|-------------------------|-------------------------|-------------------------|
| Particulars | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
| i) Financial assets - Current | | | 2021 |
| Trade receivables | 1,076.44 | 855.38 | 367.65 |
| Cash and cash equivalents | 15.45 | 2.93 | 4.18 |
| Bank Balances | 354.24 | 113.64 | 45.82 |
| Other Bank balances | 10.11 | 3.74 | 1.52 |
| ii) Financial liabilities - Current | | | |
| Trade payables | 168.78 | 204.12 | 165.33 |
| Borrowing | 631.82 | 508.06 | 223.91 |
| Lease Liabilities | 20.45 | 19.12 | 18.26 |
| Other financial liabilities | 142.40 | 145.36 | 107.20 |

(ii) Valuation techniques used to determine Fair value

The Company maintains policies and procedures to value financial assets or financial liabilities using the best and most relevant data available. The fair values of the financial assets and liabilities are included at the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note 31(ii): FINANCIAL RISK MANAGEMENT

The Company's principal financial liabilities other than derivatives comprise loans and borrowings trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include Lease assets, loans trade and other receivables and cash and cash equivalents that are derived directly from its operations.

The Company's financial risk management is an integral part of how to plan and execute its business strategies. The Company is exposed to market risk credit risk and liquidity risk. The company's focus is to foresee the unpredictability of financial markets and seek to minimize potential adverse effects on its

The Company's principal financial liabilities comprise borrowings trade and other payables. The main purpose of these financial liabilities is to manage finances for the Company's operations. The Company principal financial asset includes loan trade and other receivables and cash and short-term deposits that arise directly from its operations.

The Company's activities are exposed to market risk, credit risk and liquidity risk.

I Market riek

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise three types of risk: currency rate risk interest rate risk and other price risks such as equity price risk and commodity price risk. Financial instruments affected by market risk include loans and borrowings deposits investments and derivative financial instruments.

The sensitivity of the relevant profit or loss item is the effect of the assumed changes in respective market risks.

(a) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. In order to optimize the Company's position with regard to interest income and interest expenses and to manage the interest rate risk treasury performs a comprehensive corporate interest rate risk management by balancing the proportion of the fixed rate and floating rate financial instruments in its total portfolio.

(i) The exposure of group borrowings to interest rate changes at the end of reporting period are as follows (except for lease liabilities)

| Particulars | As at March 31, 2023 | As at March 31 2022 | As at March 31 2021 |
|--------------------------|----------------------|------------------------|------------------------|
| Variable rate borrowings | 2,628,62 | 2,503.72 | 868.31 |
| Fixed rate borrowings | 12.43 | 26.52 | 992.79 |
| Total borrowings | 2,641.06 | 2,530.24 | 1,861.09 |

(ii) As at the end of reporting period the company had the following variable rate borrowings and interest rate swap contracts outstanding:

| A 70 0 | As at March 31, 2023 | | | As at March 31 2022 | | |
|----------------------------------------------|--------------------------------------|----------|------------------|--------------------------------------|----------|------------------|
| Particulars | Weighted average interest rate | Balance | % of total loans | Weighted average interest rate | Balance | % of total loans |
| Borrowings % of total loans | 9.57% | 2,628.62 | 99.53% | 6.73% | 2,503.72 | 98.95% |
| Net exposure to cash flow interest rate risk | | 2,628.62 | | | 2,503.72 | |

| | As at March 31 2021 | | | |
|----------------------------------------------|--------------------------------------|---------|------------------|--|
| Particulars | Weighted average interest rate | Balance | % of total loans | |
| Borrowings % of total loans | 11.40% | 868.31 | 46.66% | |
| Net exposure to cash flow interest rate risk | | 868.31 | | |

(iii) Sensitivity

Profit/loss is sensitive to higher/lower interest expense from borrowings as a result of changes in interest rates.

| Particulars | | Impact on Profit | before Tax for t | he FY ending |
|-------------|------------------------------------|-------------------------|-------------------------|----------------------|
| | Increase/ Decrease in Basis Points | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
| INR | +50 - 50 | 13.14 (13.14) | 12.52 (12.52) | 4.34 (4.34) |

(b) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company has no foreign currency loans in current year end and previous year. Therefore no sensitivity is provided.





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

(c) Price Risk

The company exposure to equity securities price risk arises from the investments held by company and classified in the balance sheet at fair value through profit and loss. The company does not have any investments at the current year end and previous year which are held for trading. Therefore no sensitivity is provided.

II. Credit riek

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Company. The company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral where appropriate as a means of mitigating the risk of financial loss from defaults. The company's credit risk exposure towards its counterparties are continuously monitored. Credit exposure of any party is controlled reviewed and approved by the appointed company official in this regard.

Trade receivables may be analysed as follows:

| Age of receivables | As at March 31, 2023 | As at March 31 2022 | As at March 31 2021 |
|--------------------------|----------------------|------------------------|------------------------|
| Within the credit period | | | |
| 1-180 days past due | 882.85 | 680,04 | 368.53 |
| 181-365 days past due | 220.04 | 230.97 | 19.36 |
| more than 365 days | 45.31 | 1.22 | |
| Total | 1,148.21 | 912.22 | 387.88 |

III. Liquidity Risk

Liquidity risk is defined as the risk that company will not be able to settle or meet its obligation on time or at a reasonable price. The Company's objective is to at all times maintain optimum levels of liquidity to meet its cash and collateral requirements. The Company's management is responsible for liquidity funding as well as settlement management. In addition processes and policies related to such risk are overseen by senior management. Management monitors the company's net liquidity position through rolling forecast on the basis of expected cash flows.

The table below provides details regarding the remaining contractual maturities of financial liabilities at the reporting date based on contractual undiscounted payments:

| Particulars | Within 1 year | 1-3 years | More than 3 years | Total | Carrying |
|-----------------------------|------------------|-----------|----------------------|----------|----------|
| As at March 31, 2023 | | | | | |
| Borrowings | 631.82 | 1,084.08 | 921.86 | 2,637,76 | 2,637.76 |
| Trade payables | 168.78 | - | - | 168.78 | 168.78 |
| Lease Liabilities | 20.45 | 15.91 | - | 36.36 | 36.36 |
| Other financial liabilities | 142.40 | - | - | 142.40 | 142.40 |
| Total | 963.44 | 1,099.99 | 921.86 | 2,985,29 | 2,985,29 |

| Particulars | Within 1 year | 1-3 years | More than 3 years | Total | Carrying amount |
|-----------------------------|------------------|-----------|----------------------|----------|-----------------|
| As at March 31, 2022 | | | | | |
| Borrowings | 508.06 | 1,313.03 | 760.79 | 2,581.89 | 2,581.89 |
| Trade payables | 204.12 | | | 204.12 | 204.12 |
| Lease Liabilities | 19.12 | 36,74 | - | 55.85 | 55.86 |
| Other financial liabilities | 145,36 | | - | 145.36 | 145.36 |
| Total | 876.66 | 1,349.77 | 760.79 | 2,987,23 | 2,987.24 |

| Particulars | Within 1 year | 1-3 years | More than 3 years | Total | Carrying amount |
|-----------------------------|------------------|-----------|----------------------|----------|-----------------|
| As at March 31, 2021 | | | | | |
| Borrowings | 223.91 | 1,294.77 | 342.41 | 1,861.09 | 1,861.09 |
| Trade payables | 165.33 | - | - | 165.33 | 165.33 |
| Lease Liabilities | 18.26 | 54.76 | | 73.02 | 73.02 |
| Other financial liabilities | 107.20 | - | - | 107.20 | 107.20 |
| Total | 514.70 | 1,349.53 | 342.41 | 2,206.65 | 2,206.65 |





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

Note 31 (iii) Capital Management

(A) Risk Management

The Company manages its capital to ensure that the company will be able to continue as going concerns while maximising the return to stakeholders through the optimization of the debt and equity balance.

The Company's risk management committee reviews the capital structure of the Company on a semi-annual basis. As part of this review, the committee considers the cost of capital and the risks associated with each class of capital. The Company monitors capital on the basis of following gearing ratio, which is net debt divided by total capital plus debt.

(B) Gearing ratio

The gearing ratio at end of the reporting period was as follows.

| Partciulars | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
|---------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|
| Debt* | 2,674.12 | 2,637.73 | 1,934.11 |
| Cash and bank balances (including cash and bank balances in a disposal group held for sale) | 374.32 | 117.07 | 50.00 |
| Net debt | 2,299.80 | 2,520.66 | 1,884.12 |
| Total Equity# | 1,829.64 | 1,168.85 | 806.83 |
| Net Debts and Total equity | 4,129.43 | 3,689.51 | 2,690.95 |
| Net debt to equity ratio | 55.69% | 68.32% | 70.02% |

^{*}Debt is defined as long-term and short-term borrowings including current maturities, books overdraft and lease liabilities. #Total equity (as shown in balance sheet) includes issued capital and all other equity reserves.





Annexure VI Notes to Restated Consolidated Financial Information (All amounts in million, unless otherwise stated)

32 Corporate Social Responsibility

As per Section 135 of the Companies Act, 2013, any company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities. The Board of Directors of the Company has approved the following expenditure on CSR activities.

| Particulars | For the year ended 31-March-2023 | For the year ended 31-March-2022 | For the year ended 31-March-2021 | |
|----------------------------------------------------------------------------------------|-------------------------------------|----------------------------------|-------------------------------------|--|
| Gross amount required to be spent during the year as per calculation specified for CSR | | | | |
| activities | 6.49 | 1.79 | 1.10 | |
| Amount approved by the board to be spend during the year | 6.49 | 3.00 | 1.10 | |
| -Amount spend during the period/ year | 6.70 | 3.00 | 1.10 | |
| -Shortfall at the end of period/year | 2 | | 0.00 | |

~Reasons for Shortfall

>>For the year ended 31st March 2021

The co. is obligated to spend the CSR amount in such way that it achieves its purpose of social upliftment. At times identifying and then judiciously spending money may not be possible in the given time frame. In such cases the required unspent money is spent in the following year.

*For the shortfall pertaining to 31 March, 2021 the company has deposited Rs. 2,000/- to PM Cares fund on 12/02/2022.

~Nature of CSR Activities

Amount during the year ended 31st March, 2023, 31st March, 2022 & 31 March 2021 has been paid to charitable society which works for health care of poor people.

The computation of CSR dues is based on the Profit and Loss, as made out on the basis of the already adopted accounts for the preceding financial years.

33 Disclosure as required under Notification No. G.S.R.(E) dated 4th September, 2015 as updated vide notification dated 22nd January 2019 issued by the Ministry of Corporate Affairs w.r.t MSME (As certified by the Management):

As per information available with the management, no supplier has declared MSME status. As such, this disclosure is not applicable.

| Particulars | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|
| The principal amount and interest due thereon remaining unpaid to any supplier-MSME. | | | |
| ~Principal | 15.08 | 22.81 | - |
| ~Interest | 0.13 | 0.18 | S <u>=</u> 3 |
| The amount of interest paid by the buyer in terms of Section16 of the Micro Small and Medium Enterprise Development Act, 2006 (MSMED Act) along with the amounts of payment made to the suppliers beyond the appointed day during each accounting year. | ÷ | | Ξ |
| The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed date during period) but without adding the interest specified under the MSMED Act. | - | - | - |
| The amount of interest accrued and remaining unpaid. | 0.13 | 0,18 | 2 |
| The amount of further interest remaining due and payable even in the succeeding period, until such date when the interest dues above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act. | · . | - | - |





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

34. Revenue from contracts with customers

Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contracts with customers:

| Particulars | For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|-----------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Income from medical and healthcare services Revenue from hospital & pharmacy services Less: Inter Group Revenue | 5,202.93 | 4,009.37 | 2,442.65 |
| | 5,202.93 | 4,009.37 | 2,286.74 |

Location of revenue recognition

All the business operations of the company are in India.

Timing of revenue recognition

| Particulars | For the year ended 31 | For the year ended 31 | For the year ended 31 |
|-----------------------------------------|-----------------------|-----------------------|-----------------------|
| | March 2023 | March 2022 | March 2021 |
| Services transferred at a point of time | 553.56 | 515.76 | 312.26 |

No single customer represents 10% or more of the Company's total revenue during the periods/years ended March 31, 2023, March, 2022 and 31 March 2021

Reconciliation of revenue recognised with the contracted price is as follows:

| Particulars | For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 | |
|------------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--|
| Contracted price | 5,544.87 | 4,363,00 | 2,650,74 | |
| Reduction towards variable consideration components* | - | - | 2,030.74 | |
| Discounts | (341.94) | (353.63) | (364.00) | |
| Revenue recognised | 5,202.93 | 4,009.37 | 2,286.74 | |

*Variable consideration components include discounts on the contract price.

Contract balances

| Particulars | For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 | |
|-----------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--|
| Trade receivables* | 1,148.21 | 912.22 | 367.65 | |
| Contract liabilities (advance from patients)# | 4.69 | 6.39 | 8.15 | |

Movement in contract liabilities during the period/ year:

| Particulars | For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 | |
|---------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--|
| Balance at the beginning of the period/year | 6.39 | 8.15 | 1.23 | |
| Less: Revenue recognised from above | (6.39) | (8.15) | (1.23) | |
| Add: Addition during the period/year | 4.69 | 6.39 | 8.15 | |
| Balance at the end of the period/ year | 4.69 | 6.39 | 8.15 | |

^{*} Trade receivables are non-interest bearing and are generally on terms of 30 days.

Performance obligation

The revenue from OPD services and sale of Pharmaceutical products satisfies 'at a point in time' recognition criteria as prescribed by Ind AS 115.





[#] Contract liabilities include advances received from patients for hospital services pending final billing.

Annexure VI
Notes to Restated Consolidated Financial Information
(All amounts in million, unless otherwise stated)
35. Borrowings
Details of borrowings availed by the company

| S. No | Bank/ Financial Institution | Category of Loan | Interest Rate | Secuirty & Collateral provided | Repayment Terms | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
|----------|---------------------------------------------|---------------------------------------------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|----------------------|----------------------|----------------------|
| 1 | LIC Housing Finance Ltd | Term Loan | 10.90% | Hypothecation created on hospital land & building situated at Plot No- HO-01, Sector-Omega-1, Greater noida Uttar Pradesh | EMI of Rs. 1,03,50,941 payable for the period upto Oct -2025 | | | 506.96 |
| | Maximum amoun The loan has been taken | t O/s during the period over by State Bank of | year India again | st fresh Term Loan availed from then | n | - | (501.21) | (546.01) |
| 2 | LIC Housing Finance Ltd | Term Loan | 10.90% | Hypothecation created on hospital land & building situated at Plot No- NH-01, Sector-110 Naiad and NH- 32 Sector Omega 1, Greater Naiad Uttar Pradesh | EMI of Rs 71,62,757 payable for the period up to Oct -2025 | | | 361.35 |
| | | t O/s during the period/ over by State Bank of | | st fresh Term Loan availed from then | ı | 2 | (357.47) | (387.73) |
| 3 | Kotak Mahindra Bank | Other Loan LAP- DORD | 7.50% | Hypothecation created on personal properties of promotoers | EMI of Rs 11,66,667 payable for the period up to December, 2022 | - | - | 33.12 |
| | Maximum amount This loan has been close | O/s during the period/ d by making prepayme | | e month of March, 2022 | | - | (30.06) | (45.04) |
| 4 | Indusind Bank | Other Loan CC- DORD | 9.90% | Unsecured Loan | EMI of Rs. 1,38,889 payable for the period up to December, 2022 | - | | 2.37 |
| | Maximum amount This loan has been closed | O/s during the period/ l by making prepaymen | | e month of March, 2022 | , | | (2.16) | (3.19) |
| 5 | Indusind Bank | Equipment Loan | 9.00% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 7.95 | 14.80 | 21.30 |
| | Maximum amount | O/s during the period/ | year | | | (14.24) | (20.73) | (21.30) |
| 6 | Indusind Bank | Equipment Loan | 11.00% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 3.94 | 9.27 | 14.09 |
| | Maximum amount | O/s during the period/ | year | | | (8.85) | (13.71) | (16.70) |
| 7 | Indusind Bank | Equipment Loan | 11.00% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | | 1.94 | 4.62 |
| | Maximum amount | O/s during the period/ y | vear | | | (1.70) | (4.41) | (6.08) |
| 8 | Kotak Mahindra Bank | Equipment Loan | 10.00% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | • | 5.23 | 20.91 |
| | Maximum amount | O/s during the period/y | vear | | to deplomoti, 2022 | (3.86) | (19.66) | (29.56) |
| 9 | Kotak Mahindra Bank | Equipment Loan | 10.00% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | ÷ | œ | 2.61 |
| | Maximum amount | O/s during the period/y | ear | I I | , | - | (2.24) | (5.14) |
| | SREI Equipment Finance Limited | Equipment Loan | 12.00% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 8.12 | 17.73 | 27.74 |
| | Maximum amount | O/s during the period/y | ear | es seas | | (16.96) | (27.08) | (37.20) |





Annexure VI
Notes to Restated Consolidated Financial Information
(All amounts in million, unless otherwise stated)
35. Borrowings
Details of borrowings availed by the company

| S. | Bank/ Financial | | Interest | | | | | |
|-----|---------------------------------------------------------------------|----------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------|----------------------|----------------------|
| _No | Institution | Category of Loan | Rate | Secuirty & Collateral provided | Repayment Terms | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
| 11 | SREI Equipment Finance Limited | Equipment Loan | 12.00% | Hypothecation created on the assets purchased out of the proceeds of the loan. | EMI of Rs. 15,59,588 payable for the period up to September -2021 | | 9 | 7.77 |
| | Maximum amount (|)/s during the period/ | year | TOWN. | to september -2021 | | (4.71) | (25.94) |
| | | | | Mar. 12 2 | | | (4.71) | (23.94) |
| 12 | Punjab National Bank | Vehicle Loan | 8.55% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 2.83 | 4.23 | - |
| | waximum amouni C |)/s during the period/ | year | | | (4.16) | (5.05) | - |
| 13 | Axis Bank Ltd | Vehicle Loan | 8.35% | Hypothecation created on the assets purchased out of the proceeds of the loan. | EMI of Rs. 1,83,999 payable for the period up to September, 2025 | 4.76 | 6.66 | 8.24 |
| | Maximum amount C |)/s during the period/y | vear | | | (6.52) | (8.11) | (9.00) |
| 14 | Bank of Baroda | Vehicle Loan | 7.45% | Hypothecation created on the assets purchased out of the proceeds of the loan. | EMI of Rs. 1,06,776 payable for the period up to February, 2026 | 3.32 | 4.23 | 5.26 |
| | Maximum amount O | s during the period/y | vear | | ,, ==== | (4.26) | (5.18) | (5.36) |
| 15 | HDFC Bank Limited | Vehicle Loan | 8.00% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | (0.00) | 1.03 | 2.78 |
| | Maximum amount O | s during the period/y | rear | | | (0.88) | (2.66) | (4.05) |
| 16 | HDFC Bank Limited Maximum amount O. | Vehicle Loan //s during the period/y | 9.10% ear | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 0.85 | 1.33 | 1.77 |
| | | | | | | (1.29) | (1.73) | (2.10) |
| 17 | HDFC Bank Limited | Vehicle Loan | 8.50% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 0.19 | 0.92 | 1.60 |
| | Maximum amount O | s during the period/y | ear | | | (0.87) | (1.54) | (2.17) |
| 18 | HDFC Bank Limited Maximum amount Of This loan has been closed by | Vehicle Loan 's during the period/yo y making prepayment | 10.00% ear during the | Hypothecation created on the assets | EMI of Rs. 31,810 | | (0.73) | 0.74 (0.93) |
| 19 | HDFC Bank Limited Maximum amount O/ This loan has been closed by | Vehicle Loan s during the period/ye making prepayment | ear | Hypothecation created on the assets month of December, 2021 | EMI of Rs. 31,810 | | (0.73) | 0.74 (0.93) |
| 20 | HDFC Bank Limited | Vehicle Loan | 10.00% | Hypothecation created on the assets purchased out of the proceeds of the | | 3 3 | 0.36 | 0.61 |
| | Maximum amount 0/3 | s during the period/ye | ear | | | (0.34) | (0.61) | (0.75) |
| | HDFC Bank Limited Maximum amount O/S This loan has been closed by | Vehicle Loan s during the period/ye making prepayment | ar | Hypothecation created on the assets month of November, 2021 | EMI of Rs. 81,625 | - | (0.51) | 0.57 (1.24) |





Annexure VI
Notes to Restated Consolidated Financial Information
(All amounts in million, unless otherwise stated)
35. Borrowings

| 33. DUI | TOWINGS |
|---------|--------------------------------------|
| Details | of borrowings availed by the company |

| S. No | | Category of Loan | Interest Rate | Secuirty & Collateral provided | Repayment Terms | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
|----------|-----------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|
| 22 | HDFC Bank Limited Maximum amount This loan has been closed | Vehicle Loan O/s during the period/y l by making prepaymen | 8.60% year nt during th | Hypothecation created on the assets | s EMI of Rs. 15,490 | - | (0.25) | 0.26 (0.40) |
| 23 | HDFC Bank Limited Maximum amount | Vehicle Loan O/s during the period/ | 9.00% year | Hypothecation created on the assets | EMI of Rs. 17,020 | | (0.14) | 0.15 (0.31) |
| | This loan has been closed | l by making prepaymen | t during th | he month of December, 2021 | | | (0.14) | (0.31) |
| 24 | | Vehicle Loan O/s during the period/y by making prepaymen | | Hypothecation created on the assets to month of December, 2021 | EMI of Rs. 17,020 | 2 | (0.14) | 0.15 (0.31) |
| 25 | Ratnakar Bank Limited Maximum amount This loan has been closed | Business Loan O/s during the period/ y by making prepaymen | | Unsecured Loan se month of March, 2022 | EMI of Rs. 1,36,711 | : | (1.39) | 1.50 (2.85) |
| 26 | | Business Loan O/s during the period/y | ear | Unsecured Loan | EMI of Rs. 1,50,960 | ē | (1.37) | 1.47 (2.67) |
| | | | | e monin of December, 2021 | | | | |
| 27 | Tata Capital Financial Maximum amount | Business Loan O/s during the period/y | 13.50% rear | Unsecured Loan | EMI of Rs. 2,38,885 | - | (1.04) | 1.30 (3.07) |
| 28 | ICICI Bank Limited Maximum amount This loan has been closed | Business Loan O/s during the period/ y by making prepayment | | Unsecured Loan e month of March, 2022 | EMI of Rs. 87,365 | 2 | (1.66) | 1.73 (2.47) |
| 29 | | Business Loan | External Bench Mark+ 2.70% | Secured Loan | EMI of Rs. 12,07,018 payable for the period up to January, 2029 | 70.50 | 79.15 | - |
| | Maximum amouni | O/s during the period/ y | ear | | | (78.39) | (80.00) | · • |
| 30 | | Overdraft/ Cash O/s during the period/ye | 8.50% ear | Secured Loan | | 97.79 (100.00) | 100.46 (100.46) | |
| 31 | State Bank of India Maximum amount (| Term loan O/s during the period/ye | 8.50% ear | Secured Loan | EMI of Rs. 78,82,887 | 234.43 (303.67) | 310.06 (329.40) | #1 #1 |
| 32 | State Bank of India Maximum amount (| Term loan O/s during the period/ye | 8.50% ear | Secured Loan | EMI of Rs. 1,09,98,265 | 327.48 (424.11) | 433.03 (460.00) | # F |
| 33 | State Bank of India | Medical Equipment Loan | 8.50% | Secured Loan | Total facility available is of Rs. 7 Crores but till 31st March, 2022 facility utilised for Rs. 4.67 Crores | 39.08 | 46.79 | - |
| | Maximum amount (|)/s during the period/ ye | ear | | | (50.91) | (46.79) | |
| 34 | State Bank of India | Medical Equipment Loan | 9.25% | GECL | Total facility available is of Rs. 7 Crores but till 31st March, 2022 facility utilised for Rs. 4.67 | 265.00 | - | - |
| | Maximum amount C |)/s during the period/ ye | ar | | Crores | (265.00) | - | - |
| 35 | Indusind Bank | Equipment Loan | 11.00% | Hypothecation created on the assets purchased out of the proceeds of the | payable for the period up | . 66.91 | - | - |
| | Maximum amount O | /s during the period/ye | | loan. | to December-2022 | (72.50) | | |
| | | | | 6 | | | | |
| 36 | Punjab National Bank | Vehicle Loan | 6.85% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 0.56 | 0.63 | |
| | Maximum amount 0 | s during the period/yea | | Section 1 | 35 - 1990 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 18 | (0.62) | (0.66) | |
| | | | | | | | | |





Annexure VI Notes to Restated Consolidated Financial Information (All amounts in million, unless otherwise stated)

35. Borrowings
Details of borrowings availed by the company

| S. | | Category of Loan | Interest Rate | Secuirty & Collateral provided | Repayment Terms | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
|----|---------------------------------------------------------------|--------------------------------------|------------------|----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|
| 37 | Punjab National Bank | Vehicle Loan | 6.85% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 0.56 | 0.63 | e - |
| | Maximum amouni | t O/s during the period/ | year | | 10 110 venibel, 2020 | (0.62) | (0.66) | - |
| 38 | Punjab National Bank | Vehicle Loan | 6.85% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 0.56 | 0.63 | = |
| | Maximum amount | O/s during the period/ | year | | | (0.62) | (0.66) | - |
| 39 | Punjab National Bank | Vehicle Loan | 6.85% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 0.55 | 0.63 | |
| | Maximum amount | O/s during the period/ | year | | | (0.61) | (0.66) | - |
| 40 | | Vehicle Loan O/s during the period/ | 6.85% year | Hypothecation created on the assets | EMI of Rs. 9,980 | 0.56 (0.62) | 0.62 (0.65) | ĵ |
| 41 | Punjab National Bank Maximum amount | Vehicle Loan O/s during the period/y | 6.85% year | Hypothecation created on the assets | EMI of Rs. 32,000 | . 1.83 (2.03) | 2.05 (2.10) | - |
| 42 | Punjab National Bank Maximum amount | Vehicle Loan O/s during the period/y | 6.85% vear | Hypothecation created on the assets | EMI of Rs. 32,000 | 1.83 (2.03) | 2.05 (2.10) | |
| 43 | Dr. Ajay Kumar Tyagi Maximum amount | O/s during the period/ y | vear | Unsecured Loan | | (8.70) | 8.70 (8.70) | ** |
| 44 | 4 Dr. Kapil Kumar Maximum amount O/s during the period/ year | | | Unsecured Loan | | (10.44) | 10.44 (10.44) | (#) |
| 45 | Yatharth Tyagi Maximum amount | O/s during the period/y | vear | Unsecured Loan | | (32.50) | 32.50 (32.50) | * |
| 46 | The Nainital Bank Ltd | Term Loan | 10.65% | Land & Building of the Project and personal properties and guarantees of the promoters | Monthy payments of principals and interest as per the terms agreed with the banks. The entire loan amount to be paid by May, 2028 | | | 473.18 |
| | Maximum amount (| O/s during the period/y | ear | | | | (477.71) | (515.26) |
| 17 | Punjab National Bank | Term Loan | 9.80% | equipment | Monthy payments of principals and interest as per the terms agreed with the banks. The entire loan amount to be paid by Sep, 2028 | . 233.76 | 254.74 | 280.55 |
| | Maximum amount (|)/s during the period/ye | ear | | | (252.76) | (280.55) | (281.30) |





Annexure VI Notes to Restated Consolidated Financial Information (All amounts in million, unless otherwise stated)

35. Borrowings
Details of borrowings availed by the company

| S. No | | Category of Loan | Interest Rate | Secuirty & Collateral provided | Repayment Terms | As at March 31, 2023 | As at March 31, 2022 | As at March 31, 2021 |
|----------|----------------------------------------|----------------------------------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|
| 48 | SREI Equipment Finance Limited | Equipment Loan | 12.00% | Hypothecation created on the assets purchased out of the proceeds of the loan. | payable for the period up | 4.31 | 8.79 | 12.69 |
| | Maximum amount | O/s during the period/ | / year | ioaii. | to Jan -2023 | (8.45) | (12.69) | (16.33) |
| 49 | Tata Capital Financial Services Ltd | Equipment Loan | 6.30% | Hypothecation created on the assets purchased out of the proceeds of the loan. | | 39.58 | 51.65 | 65.61 |
| | Maximum amount | O/s during the period/ | year | | | (50.59) | (65.61) | (73.91) |
| 50 | Punjab National Bank | Term Loan | 9.25% | Working Capital Term Loan under Guaranteed Emergency Credit Line (GECL) 2.0 | EMI of Rs 47,10,417/- plus applicable interest payable monthly starting from December, 2023 for the period up to Dec - 2027. | 226.01 | 225.95 | - |
| | Maximum amount (|)/s during the period/ | year | | 2021. | (227.40) | (226.10) | (4) |
| 51 | Punjab National Bank | Term Loan | 9.80% | Land & Building of the Project and personal properties and guarantees of the promoters. Term loan has been taken over by Punjab National bank from The Nainital Bank in December, 2021. | Monthy payments of principals and interest as per the terms agreed with the banks. The entire loan amount to be paid by April,2027 | 393.45 | 443.92 | |
| | Maximum amount (|)/s during the period/ | year | | | (446.40) | (455.60) | - |
| 52 | Punjab National Bank Maximum amount C | Term Loan 3/s during the period/ | 9.80% year | Project loan taken for finishing of | Monthy payments | 20.88 (29.63) | - | * |
| 53 | Indusind Bank | Equipment Loan | 8.25% | Hypothecation created on the assets purchased out of the proceeds of the loan. | Amount of Rs 1,68,260/- plus applicable interest payable at monthly rest. The entire loan is to be cleared by the period Aug, 2026 | 5.88 | | - |
| | Maximum amount C | s during the period/ | year | | | (6.86) | | 12 |
| 54 | Punjab National Bank | Overdraft/ Cash Credit Facility | 9.80% | Secured Loan | | 43.65 | - | _ |
| | Maximum amount O | s during the period/y | year | | | (50.00) | | 2 |
| 55 | Tata Capital Financial Services Ltd | Equipment Loan | 10.50% | Hypothecation created on the assets purchased out of the proceeds of the loan. | Amount of Rs 6,58,629/- plus applicable interest payable at monthly rest. The entire loan is to be cleared by the period Nov, 2027 | 28,67 | | |
| 56 | Maximum amount O | s during the period/y | | Hypothecation greated as the access | | (41.22) | - | - |
| | | Equipment Loan /s during the period/ y | | Hypothecation created on the assets | Amount of Ks 49,131/- | 2.14 (2.14) | - | - |
| 57 | Punjab National Bank | Term Loan | 10.80% | Hypothecation created on hospital land & building situated at Orcha, | | 481.62 | 504.85 | 8 - 1 |
| | Maximum amount O | s during the period/y | | Jhansi | | (508.30) | (504.85) | |
| | | G F J | | | | (300.30) | (20.4.03) | |
| 58 | Punjab National Bank | Term Loan | 10.80% | Hypothecation created on hospital land & building situated at Orcha, Jhansi | | 21.51 | - | |
| | Maximum amount O | s during the period/y | vear | | | (50.00) | | |
| | | | | | | | | |





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

36. Related Party Transactions

a) Names of the related parties and description of relationship:

Key managerial personnel (KMP) of Holding Company

Yatharth Hospital & Trauma Care Services Limited

- 1. Dr. Ajay Kumar Tyagi
- Dr. Kapil Kumar
 Dr. Neena Tyagi
- 4. Dr. Manju Tyagi
- 5. Mr. Yatharth Tyagi
- 6. Dr. Sanjeev Upadhyaya
- 7. Mr. Mukesh Sharma
- 8. Dr. Ila Patnaik
- 9. Mrs Promila Bharadwaj
- 10. Mr Ritesh Mishra
- 11. Mr. Amit Kumar Singh
- 12. Mr. Pankaj Prabhakar
- 13. Mr. Deepak Kumar Tyagi

Key managerial personnel (KMP) of Subsidiary Company

a) AKS Medical & Research Private Limited

- 1. Dr. Ajay Kumar Tyagi
- 2. Dr. Kapil Kumar
- 3. Dr. Neena Tyagi
- 4. Dr. Manju Tyagi
- Dr. Sanjeev Upadhyaya
 Mr. Deepak Kumar Tyagi

b) Sanskar Medica India Limited

- 1. Dr. Ajay Kumar Tyagi
- 2. Dr. Kapil Kumar
- 3. Dr. Neena Tyagi
- 4. Dr. Manju Tyagi

c) Ramraja Multispeciality Hospital & Trauma Centre Private Limited

- 1. Dr. Ajay Kumar Tyagi
- 2. Dr. Kapil Kumar
- 3. Dr. Pradeep Jain
- 4. Mayank Gupta
- 5. Alka Jain
- 6.Dr. Ila Patnaik
- 7.Mrs Promila Bharadwaj

Relative of key managerial personnel

- 1. Mr. Sanskar Tyagi
- 2. Mr. Lal Chand Tyagi
- 3. Mrs. Shilpi Singh

Enterprise exercising significant influence on the Company

Nı

Enterprises where key managerial personnel along with their relatives exercise significant influence

No such enterprise



Nature of Relationship

Chairman

Managing Director

Director (upto 05.08.2021)

Director (upto 05.08.2021)

Director (w.e.f. 15.09.2021)

Independent Director (w.e.f. 21.02.2022)

Independent Director (w.e.f. 21.02.2022)

Independent Director (from 21.02.2022 to 02.08.2022)

Independent Director (w.e.f. 22.10.2022)

Company Secretary & Compliance Officer

Chief Executive Officer (w.e.f. 15.09.2021)

Chief Financial Officer (w.e.f. 21.02.2022)

President- Strategy & Finance (w.e.f 01.02.2022)

Nature of Relationship

Director

Director

Director

Director

Independent Director (w.e.f. 07.03.2022)

President- Strategy & Finance (from 16.06.2021 to 31.01.2022)

Director

Director

Director

Director

Director (w.e.f. 28.01.2022)

Director (w.e.f. 28.01.2022)

Director (upto 18.02.2022)

Director (upto 18.02.2022)

Director (upto 18.02.2022)

Independent Director (w.e.f 07.03.2022 to 02.08.2022)

Independent Director (w.e.f. 12.11.2022)



Annexure VI
Notes to Restated Consolidated Financial Information
(All amounts in million, unless otherwise stated)

(b) Following is the summary of significant related party transactions during the year:

| | | | 72 |
|------------------------------------------------------------------|----------------------------------|-------------------------------------|-------------------------------------|
| | For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
| Remuneration to KMPs & Relatives of KMPs | et e | | |
| Dr. Ajay Kumar Tyagi | 12.00 | 12.00 | 7.20 |
| Dr. Kapil Kumar | 12.00 | 12.00 | 7.20 |
| Dr. Manju Tyagi | 12.00 | 12.00 | 7.20 |
| Dr. Neena Tyagi | 12.00 | 12.00 | 7.20 |
| Mr. Yatharth Tyagi | 12.00 | 7.00 | 4.80 |
| Mr. Sanskar Tyagi | <u> </u> | - | 0.60 |
| Mr. Ritesh Mishra- Company Secretary | 0.78 | 0.78 | 0.69 |
| Mr. Amit Kumar Singh | 2.38 | 1.32 | - |
| Mr. Pankaj Prabhakar | 2.85 | 0.48 | - |
| Mrs. Shilpi Singh | 1.46 | * | 19 4 0 |
| Mr. Deepak Kumar Tyagi | 8.00 | 6.33 | |
| Rent paid to KMP | | | |
| Dr. Ajay Kumar Tyagi | - | - | 0.84 |
| Dr. Kapil Kumar | 9.70 | - | 0.84 |
| Dr. Manju Tyagi | :- | - | 0.42 |
| Dr. Neena Tyagi | | • | 0.42 |
| Director sitting fees paid | | | |
| Mr. Mukesh Sharma | 0.30 | 0.18 | |
| Dr. Ila Patnaik | - | 0.18 | |
| Mrs Promila Bharadwaj | 0.30 | 0.10 | |
| Dr. Sanjeev Upadhyaya | 0.14 | - | - |
| Investment in Equity Shares | | | |
| AKS Medical & Research Centre Private Limited | | - | 11.31 |
| Ramraja Multispeciality Hospital & Trauma Centre Private Limited | - | 37.71 | - |
| Purchase of Equity shares of (AKS) Dr. Ajay Kumar Tyagi | - | 56.64 | - |
| Purchase of Equity shares of (AKS) Dr. Kapil Kumar | - | 32.56 | - |
| Loans and Advances- Subsidiary Company | | | |
| AKS Medical & Research Private Limited | | | |
| Loans and Advances- Received | 428.60 | 633.53 | 331.85 |
| Loans and Advances- Paid Back | 560.79 | 503.44 | 331.85 |
| Loans and Advances- Given | - | - | 86.58 |
| Loans and Advances- Received Back | - | - | 86.58 |
| Sanskar Medica India Limited | | | |
| Loans and Advances- Received | | - | 18.70 |
| Loans and Advances- Paid Back | . | | 3 8 - |
| Loans and Advances- Given | 0.05 | . 9 | - |
| Loans and Advances- Received Back | - | - | - |
| Ramraja Multispeciality Hospital & Trauma Centre Private Limited | ** | (20.7) | |
| Loans and Advances- Given | 153.37 | 268.34 | - |
| Loans and Advances- Received Back | 14.54 | - | - |





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

| Loans and Advances received from KMP's & Relatives of KMP's Dr. Ajay Kumar Tyagi Dr. Kapil Kumar Yatharth Tyagi Mr. Lal Chand Tyagi* *Loan was taken in FY 2019-20 and negative figure denotes repayment of the same. c) The Company has the following amounts due from/ to the related parties: | (8.70) (10.44) (32.50) | 8.70 10.44 32.50 | - - (0.40) |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------------------------------|------------------------------------|
| y and the tollowing amounts due from to the related parties; | As at 31 March 2023 | As at 31 March 2022 | As at 31 March 2021 |
| Trade payables AKS Medical & Research Centre Private Limited | | | - |
| Borrowings (Current) AKS Medical & Research Private Limited Sanskar Medica India Limited Dr. Ajay Kumar Tyagi Dr. Kapil Kumar Yatharth Tyagi | 56.10 | 130.09 56.10 8.70 10.44 32.50 | 56.10 |
| Amount Receivable Sanskar Medica India Limited Ramraja Multispeciality Hospital & Trauma Centre Private Limited AKS Medical & Research Private Limited | 1.11 407.17 2.09 | 1.06 268.34 | 1.06 - - |
| Remuneration payable to KMP Dr. Ajay Kumar Tyagi Dr. Kapil Kumar Mr. Yatharth Tyagi Mr. Ritesh Mishra- Company Secretary Mr. Amit Kumar Singh Mr. Pankaj Prabhakar Mrs. Shilpi Singh Dr. Neena Tyagi Dr. Manju Tyagi | 0.06 · 0.18 0.22 0.01 | 0.73 1.39 0.16 0.06 - 0.05 - 4.22 6.59 | - - 0.08 - - - - |
| Director sitting fees payable Mr. Mukesh Sharma Dr. Ila Patnaik Mrs Promila Bharadwaj Dr. Sanjeev Upadhyaya | 0.13 - 0.16 0.13 | 0.12 0.12 - | |

f) All transactions with these related parties are at arm's length basis and resulting outstanding receivables and payables including financial assets and financial liabilities balances are settled in cash. None of the balances are secured. (All the amounts of transactions and balances disclosed in this note are gross and undiscounted.)





Annexure VI Notes to Restated Consolidated Financial Information

Note 37: Employee benefit plans The employee benefit schemes are as under: **Defined Retirement Plans** (1) Provident Fund

The benefit of Provident Fund is extended to all such eligible employees, as is defined under the relevant regulations under the applicable the provisions of Provident Fund Act and the Rules and ESIC. Amount debited to Profit and Loss account including Administrative and Employees Deposit Linked Insurance charge and ESIC amounts to Rs 2.03/- during the period (FY- 2021-22 - Rs 0.74/- & 2020-21 - Rs 0.29/-).

(2) Gratuity
Gratuity - The liability for Gratuity is provided on the basis of Actuarial Valuation made at thend of each financial year. The Actuarial Valuation is made on Projected Unit Credit method as per Ind AS 19.

Reconciliation of opening and closing balances of the present value of the defined benefit obligation:

| | For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|-----------------------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Opening defined benefit obligation | 9.83 | 0.46 | 0.37 |
| Current service cost | 7.09 | 13.11 | 0.09 |
| Interest Cost | 0.67 | 0.03 | 0.02 |
| Actuarial (gain)/loss Benefits paid | (4.01) | (3.77) | (0.02) |
| Benefit obligation at the end of the period/year | 13,57 | 9.83 | 0.46 |
| Provision (Current) Refer Note No22 | 0.59 | 0.05 | 0.06 |
| Provision (Non- Current) Refer Note No16 | 12.99 | 9.78 | 0.41 |
| Gratuity expense recognised in the statement of profit and loss | | | |
| | | | |

Current service cost Interest on defined benefit obligation

Net actuarial (gain)/loss recognised in the period/year Net gratuity expenses

Re-measurements recognised in other comprehensive income

Actuarial (gain)/loss on defined benefit obligation Return on plan assets excluding interest income
Actuarial (gain)/loss recognised in other comprehensive income

Summary of actuarial assumptions Financial assumptions at balance sheet date:

| Discount rate | |
|------------------------|----------------|
| Salary escalation rate | |
| Attrition rate | |
| | Age 18 to 30 |
| | Age 30 to 45 |
| | Above 45 Years |

Maturity profile of defined benefit obligation

| 1st following year |
|--------------------|
| Year 2 to 5 |
| Year 6 to 10 |
| More than 10 years |

Retirement Age

| For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|-------------------------------------|-------------------------------------|-------------------------------------|
| 7.09 | 13.11 | 0.09 |
| 0.67 | 0.03 | 0.02 |
| (4) | | |
| 7.75 | 13 14 | 0.11 |

| For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|-------------------------------------|-------------------------------------|-------------------------------------|
| (4.01) | (3.77) | (0.02) |
| - | - | |
| (4.01) | (3.77) | (0.02) |

| | For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|-------|-------------------------------------|-------------------------------------|-------------------------------------|
| -),- | 7.30 | 6.75 | 6.48 |
| | 5.00% | 5.00% | 7.00% |
| | | | |
| | 13.00% | 13.00% | 10.00% |
| | 13.00% | 13.00% | 10.00% |
| | 13.00% | 13.00% | 10.00% |
| | 60 Years | 60 Veare | 60 Vaara |

| For the year ended 31 March 2023 | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|-------------------------------------|-------------------------------------|-------------------------------------|
| 0.59 | 0.05 | 0.06 |
| 7.15 | 1.99 | 0.32 |
| 10.37 | 8.63 | 0.41 |
| 7.44 | 5 | - |

Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations. Salary escalation rate: The estimates of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors.

Sensitivity analysis: Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant would have affected the defined benefit obligation by the

| | For the year ended | For the year ended 31 March 2023 | | For the year ended 31 March 2022 | | For the year ended 31 March 2021 | |
|-------------------------------------------|--------------------|----------------------------------|----------|----------------------------------|----------|----------------------------------|--|
| | Increase | Decrease | Increase | Decrease | Increase | Decrease | |
| Discount rate (100 bps movement) | 9.82 | 11.35 | 7.50 | 9.03 | 0.04 | 0.04 | |
| Salary escalation rate (100 bps movement) | 11.24 | 9.92 | 9.04 | 7.48 | 0.04 | 0.04 | |

Expected contributions to the plan for the next annual reporting period

| For the year ended | For the year ended | For the year ended |
|--------------------|--------------------|--------------------|
| 31 March 2023 | 31 March 2022 | 31 March 2021 |

Expected contributions to the plan for the next annual reporting period





Annexure VI Notes to Restated Consolidated Financial Information

38. Contingent Liabilities

a) Bank & Corporate Guarantees

| Particulars | As on 31st March, 2023 | As on 31st March, 2022 | As on 31st March, 2021 | |
|----------------------------------|---------------------------|---------------------------|---------------------------|--|
| Bank Guarantees (BG) | 109.24 | 90.79 | 86.29 | |
| Margin Money against above BG | 23.28 | 16.19 | 12.68 | |
| Corporate Guarantee (CG) | 2885.37 | 1390.60 | 865.00 | |
| Outstanding against the above CG | 2249.20 | 1154.10 | 819.34 | |

b) Other contingent liabilities

- A case has been filed within the jurisdiction of Gautam Budh Nagar, Uttar Pradesh against a director and the doctors of the company for medical negligence. The opponent party has not specified any compensation for the said alleged medical negligence.
- ii. First Information Report dt. November 19, 2022 has been filed against the doctors and the management of the Company for medical negligence. The complainant has made a claim of Rs 5.00 million in consumer court along with 9% interest per annum.

Note:- For all the contingent liabilities mentioned hereinabove, the Company believes that it is not liable to pay any amount and has not provided any sum for these liabilities in its books of accounts. The Company is dealing with these cases at appropriate legal forum

c) Claim against the company not acknowledged as debts

i) The company had been served a Show Cause Notice u/s 279(1) of the Income Tax Act, 1961 that the company has defaulted in the payment of TDS as under:*

| S. No Financial Year | | Financial Year Amount of tax deposited after the due date, as per rule 30 of the Income Tax Act, 1961 | |
|----------------------|---------|-------------------------------------------------------------------------------------------------------|------|
| 1 | 2012-13 | 3.27 | 0.35 |
| 2 | 2013-14 | 7.12 | 0.87 |
| 3 | 2014-15 | 10.62 | 1.51 |
| 4 | 2016-17 | 14.39 | 1.27 |

^{*} The company had been served a Show Cause Notice u/s 279(1) of the Income Tax Act, 1961 that the company has defaulted in the payment of TDS. The company has already paid the delayed principal amount of TDS and the interest amount thereon. Though the due principal amount of TDS and the interest has been paid, the matter is yet to be closed by the Income Tax Department. The matter has since been settled with Income Tax Department at no additional cost to the Company This prosecution preceding is dropping u/s 276B.





Annexure VI Notes to Restated Consolidated Financial Information

ii) The company has been served a notice u/s 17 of The Consumer Protection Act, 1986, wherein the following amounts have been demanded by the counter party.**

| Particulars | As on 31st March, 2023 | As on 31st March, 2022 | As on 31st March, 2021 |
|---------------------------------------|------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Cost of Medical Treatment | Nil | 2.28 along with interest from 23.02.2018 and pendente lite interest thereto | 2.28 along with interest from 23.02.2018 and pendente lite interest thereto |
| Towards agony and harassment suffered | Nil | 5.00 | 5.00 |

^{**}Notice u/S 17 of the Consumer Protection Act, 1986 is closed on 13/10/2022.

d) Capital Commitments

- iii) The group has been allotted Plot No- NH-31 in Sector Omega-1, Greater Noida by Greater Noida Industrial Development Authority (GNIDA) for a total amount of Rs. 76.27 million on 18th March, 2023. The group has already deposited Rs. 6.41 million by 31st March, 2023. Further the balance was to be paid within 90 days from the date of issue of allotment letter which has already been paid by the group.
- iv) The group has capital commitments of Rs 344.45 million (net of advance paid) (previous year Rs 326.60) for purchase of hospital equipment.
- v) The group has imported Capital Goods under Export Promotion Capital Goods Scheme [EPCG], where-under the Company is required to fulfil export obligation/deemed exports amounting to Rs 62.36 million [Previous Year `Nil]. The liability amounting to Rs 62.36 million [Previous Year Nil] on account of custom duty may arise along with interest @15% p.a., in the event of non-fulfilment of export obligation. The group has completed export obligation amounting to Rs NIL upto end of this financial year and submitted the relevant documents with Director General Foreign Trade for seeking fulfilment of export obligation certificate.
- 39. There is no impairment loss on fixed assets on the basis of review carried out by the management in accordance with IND AS 36.
- 40. Balances of certain trade receivables, loans & advances, advances received from customers and trade payables are subject to confirmation, if any. The management does not expect any material difference affecting the financial statements on such adjustments.

41. Covid 19 business and government guidelines

During the financial year 2022-23, the group has not treated any patient infected with Covid-19, whereas during the financial year 2021-22 the company had admitted and treated Covid-19 infected patients. There has been government guidelines related to the treatment and the cost of treatment of Covid 19 Patients. The Company has followed all such guidelines.

42. Foreign exchange earning and outgo

a) Foreign exchange earnings & outgo is as follows:





Annexure VI Notes to Restated Consolidated Financial Information

| Particulars | 31st March, 2023 | 31st March, 2022 | 31st March, 2021 |
|--------------------------------------------|------------------|------------------|------------------|
| Cost of Medical Equipment | 41.21 | - | 10.01 |
| Income in Foreign Exchange | 3.21 | - | - |
| Advance for Purchase of Medical Equipments | - | 3.00 | - |

43. Covid 19 and grant for moratorium to pay principal and interest on outstanding loan

During the financial year 2019-2020 and 2020-2021, Covid 19 affected the overall business cycle of the economy. To address to liquidity concern of the businesses, the Reverse Bank of India wide its circulars; DOR.No.BP.BC.47/21.04.048/2019-20 March 27,2020, Circular DOR.No.BP.BC.63/21.04.048 /2019-20 April 17, 2020, DOR. No.BP.BC.71/21.04.048/2019-20 May 23, 2020, allowed the moratorium to pay the due principal and interest on outstanding loans. The Company availed the benefits of given moratorium to the extent of Rs. 121.77 Millions (inclusive of principal and interest). The amount covered under the moratorium shall be paid by extending the overall term of the respective loan account.

44. Income Tax

The major components of income tax expenses are as follows:

| Particulars | As at 31st March, 2023 | As at 31st March, 2022 | As at 31st March, 2021 |
|---------------------------------|---------------------------|---------------------------|---------------------------|
| Income Tax Expense | | | |
| Current Tax: | | | |
| Current Income Tax | 246.66 | 180.09 | 50.37 |
| Income tax of earlier year | 1.61 | - | - |
| MAT credit entitlement/reversed | 11.03 | 18.02 | (16.63) |
| Deferred Tax | (40.19) | (8.68) | 51.61 |
| TOTAL | 219.10 | 189.44 | 85.36 |

The income tax expense for the year can be reconciled to the accounting profit/(loss)as follows:

| Particulars | As at 31st March, 2023 | As at 31 st March, 2022 | As at 31st March, 2021 |
|-----------------------------------------------------------------|---------------------------|---------------------------------------|---------------------------|
| Profit / (Loss) before tax as per Statement of Profit and Loss | 876.78 | 631.06 | 281.23 |
| Effective Tax Rate | 25.17% | 29.12% | 29.12% |
| Tax Effect of: | | | |
| Income tax using the Company's domestic tax rate | 220.69 | 183.76 | 81.90 |
| Tax Effect of: | | | |
| Timing Difference- Deferred Tax | (40.19) | (8.68) | 51.61 |
| Permanent Difference | 3.19 | (5.67) | (3.46) |
| Total Income Tax expenses recognized in profit and Loss account | 219.10 | 189.44 | 85.36 |
| Effective Tax Rate (%) | 24.99% | 30.02% | 30.35% |





Annexure VI

Notes to Restated Consolidated Financial Information

(All amounts in million, unless otherwise stated)

45. Ratios as per Schedule III requirement

| Current Ratio | | 2022-23 | 2021-22 | 2020-21 |
|--------------------------|---------------------------------------|--------------------|--------------------|------------------|
| Numerator Denominator | Current Assets Current Liabilities | 1,762.67 995.18 | 1,094.00 971.05 | 493.21 550.01 |
| Ratio | | 1.77 | 1.13 | 0.90 |
| %Change | | 57,21% | 25.64% | |

Reason for change: F.Y. 2021-22- The reduction in current maturities reduced the current liabilities and thus improving the current ratio.

Reason for change: F.Y. 2022-23- Relative increase in cash & cash equivallent & increase in debtors in tendem with increase in Sale, has led to higher current ratio. During the period Co preferred to payoff

its creditors and thus improving the current ratio

| Debt Equity Ratio | | | | |
|-------------------|----------------------------------------------|----------|----------|----------|
| Numerator | Long Term Borrowings + Short Term Borrowings | 2.637.76 | 2,581.88 | 1,861.09 |
| Denominator | Shareholders Funds | 1,829.64 | 1,168.85 | 806.83 |
| Ratio | | 1.44 | 2.21 | 2.31 |
| %Change | | -34 73% | -4 24% | |

Reason for change: FY 2022-23- Increased profits added to shareholders fund at the same time Co did not increase its much of itsdebt, thus leading to better Debt Equity Ratio.

| %Change | | 2.0/0/ | 05 030/ | |
|-----------------------------|---------------------------------------------------------|----------|----------|--------|
| Ratio | _ | 2.11 | 2.18 | 2.99 |
| Denominator | Principal repayments of Long term borrowings & Interest | 632.94 | 508.80 | 223.91 |
| Numerator | EBIDTA | 1,337.65 | 1,108.11 | 670.11 |
| Debt Service Coverage Ratio | | | | |
| | | | | |

Reason for change: FY 2021-22- The EBIDTA has improved over the last year significantly. During FY 2020-21, the debt obligation due to moratorium during COVID period was lower, which got back to normal during the year and thus leading to lower DSCR during the year.

| Return on Equity/ Investment Ratio | | | | | |
|------------------------------------|------------------------|--|----------|----------|--------|
| Numerator | Net Profit after Taxes | | 657.68 | 441.62 | 195.88 |
| Denominator | Shareholder's Equity | | 1,829.64 | 1,168.85 | 806,83 |
| Ratio | | | 35.95% | 37.78% | 24.28% |

Reason for change: FY 2021-22-With better revenue and profitability, the shareholder equity has increased on YoY basis

| Inventory Turnover Ratio | | | | |
|--------------------------|-------------------|----------|----------|----------|
| Numerator | Sales | 5,202.93 | 4,009.37 | 2,286,74 |
| Denominator | Average Inventory | 56.33 | 42.93 | 31.24 |
| Ratio | | 92.37 | 93.40 | 73.19 |
| %Change | | -1 10% | 27 62% | |

Reason for change: FY 2021-22- With not so much increase in the levels of inventory, better sale has been achieved and thus increasing the utilization of available inventory.

| Frade | Receivables | Turnover | Ratio |
|--------------|-------------|----------|-------|

%Change

| Numerator | Net Credit Sales | 5,202.93 | 4,009.37 | 2,286.74 |
|-------------|-------------------------|----------|----------|----------|
| Denominator | Avg Accounts Receivable | 965.91 | 611.52 | 268.34 |
| Ratio | | 5.39 | 6.56 | 8.52 |
| %Change | | -17.84% | -23.06% | |
| | | | | 7.7 |

Reason for change: - FY 2021-22- The Debtors are increasing due to increase in sale, especially on accounts with credit customers

| rade | Payables | Turnover | Ratio |
|------|----------|----------|-------|
| | | | |

| Numerator | Net Credit Purchases | | 929.35 | 813.28 | 463.18 |
|-------------|----------------------|---|--------|--------|--------|
| Denominator | Avg Trade Payables | | 186.45 | 184.73 | 151.34 |
| Ratio | | S | 4.98 | 4.40 | 3.06 |
| %Change | | | 13.22% | 43.85% | |
| | | | | | |

Reason for change: FY 2021-22- With better EBIDTA and liquidity, Company is paying its vendors at faster pace.

| M-4 (14-17 | F D - 41- | |
|-------------|-----------|--|

| %Change | | -79.21% | -180.99% | |
|----------------------------|-------------------------------------------------------|----------|----------|----------|
| Ratio | | 6.78 | 32.61 | (40.26) |
| Denominator | Working Capital (Current Assets- Current Liabilities) | 767.49 | 122.95 | (56.80) |
| Numerator | Net Sales | 5,202.93 | 4,009.37 | 2,286.74 |
| Net Capital Turnovel Ratio | | | | |

Reason for change:- FY 2021-22 and FY 2022-23- The Current ratio on account of additions in debtors and cash & cash equivallent and at the same time paying creditors with better pending creditor days, has led to better current ratio. This has led to better working capital as compared to sale

Net Profit Ratio

| %Change | | 14.76% | 28.59% | |
|------------------|------------|----------|----------|----------|
| Ratio | | 12.64% | 11.01% | 8.57% |
| Denominator | Net Sales | 5,202.93 | 4,009.37 | 2,286.74 |
| Numerator | Net Profit | 657.68 | 441.62 | 195.88 |
| Net I fort Ratio | | | | |

Reason for change:- FY 2021-22-in comparision to Sale, net profit has increased because of comaprative lower depreciation, interest and taxation

Return on Capital Employed

Numerator Denominator Ratio %Change

Earning before Interest and Taxes

Capital Employed

| a launia | 9.33% | 24.92% | |
|----------|----------|----------|----------|
| Trallm | 23.78% | 21.75% | 17.41% |
| | 4,467.39 | 3,750.73 | 2,667.92 |
| | 1,062.33 | 815.78 | 464.52 |

-4.86%

55.63%

Reason for change :- FY 2021-27-EBIDTA e capital employed, inclusive of loan and shareholde ndem. Loans are paid at the committed intervals

and the addition to shareholder n accumulated profits

ered Accou

agpal Associa

Annexure VI
Notes to Restated Consolidated Financial Information
(All amounts in million, unless otherwise stated)

46. Business Combination and Goodwill

The Company has acquired equity shares of;

- (1) AKS Medical & Research Centre Pvt Ltd (AKS) and
- (2) Ramraja Multispecialty Hospital & Trauma Centre Pvt. Ltd. (Ramraja)

AKS became 100% subsidiary on September 20th 2016. Later on, though AKS remained subsidiary of the Company, to augment its capital requirements, AKS issued equity shares to Promoters and other entities. Over a period of time to gain better control and avoid any conflict of interest, the Company acquired shares of AKS from the minority shareholders; the Promoters and non Promoter entities. The valuations of AKS was based on the valuation report of the registered valuer.

| | For the year ended March 31, 2023 | For the year ended March 31, 2022 | For the year ended March 31, 2021 |
|-------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Number of equity shares acquired/held | 4.070.000 | 4.070.000 | |
| Consideration paid (Rs million) | 4,079,000 89.20 | 4,079,000 | 595,235 |
| % of Controling stake | 100.00% | 89.20 100.00% | 11.31 80.31% |
| Value of Assets acquired (based on audited financial statements of preceeding year) | | | |
| Property Plant & Equipment (incl CWIP) | 1,183.05 | 1,183.05 | 1,068.52 |
| Current Assets other than cash & bank | 107.95 | 107.95 | 5.36 |
| Cash & cash equivallent | 43.69 | 43.69 | 10.90 |
| Total Value of assets acquired | 1,334.69 | 1,334.69 | 1,084.78 |
| Total Value of Liabilities acquired (based on LY audited financial statements) | | | |
| Bank borrowings | 768.37 | 768,37 | 745.87 |
| Other liabilities | 149.28 | 149.28 | 29.27 |
| Total Value of libailities assumed | 917.66 | 917.66 | 775.14 |
| Net Asset Value for the equity shares acquired from the minority shareholders | 92.27 | 02.27 | 0.70 |
| Amount paid for Goodwill | 82.27 6.93 | 82.27 6.93 | 9.78 1.53 |
| Total Purchase Consideration paid to minority shareholders | 89.20 | 89.20 | 11.31 |
| Cumulative amount paid for the Goodwill (A) | 11.05 | 11.05 | 4.12 |

Ramraja became 100% subsidiary on February 18th 2022. The valuation of Ramraja was arrived based on the valuation report of the regsitered valuer and the negotiations carried out between the Company and the erstwhile shareholders of the Company

| | For the year ended March 31, 2023 | For the year ended March 31, 2022 | For the year ended March 31, 2021 |
|--------------------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Number of equity shares acquired/held | 4,010,000 | 4,010,000 | |
| Consideration paid (Rs million) | 37.71 | 37.71 | |
| % of Controling stake | 100% | 100% | |
| Value of Assets acquired | | | |
| (based on provision financial statements on the date of acquisition) | | | |
| Property Plant & Equipment (incl CWIP & intangibles) | 310.05 | 310.05 | _ |
| Current Assets other than cash & bank | 0.05 | . 0.05 | - |
| Other assets- including deferred tax | 103.84 | 103.84 | - |
| Cash & cash equivallent | 115.30 | 115.30 | - |
| Total Value of assets acquired | 529.24 | 529.24 | - |
| Total Value of Liabilities acquired (based on LY audited financial statements) | | | |
| Bank borrowings (including interest) | 500.00 | 500.00 | 2 |
| Other liabilities | 377.49 | 377.49 | = |
| Total Value of libailities assumed | 877.49 | 877.49 | 3 |
| Net Asset Value for the equity shares acquired from the minority shareholders | (348.25) | (348.25) | _ |
| Amount paid for Goodwill | 385.96 | 385.96 | - |
| Total Purchase Consideration paid to minority shareholders | 37.71 | 37.71 | - |
| Cumulative amount paid for the Goodwill (B) | 385.96 | 385.96 | 0.00 |
| Total value of Goodwill carried as on the date (A+B) | 397.01 | 1 Traum 2 397.01 | 4.12 |

Annexure VI Notes to Restated Consolidated Financial Information

47. Details related to borrowings secured against current assets:

The company has given current assets (trade receivables and inventories) as security for working capital (fund and non fund-based limits) obtained from State Bank Of India & Punjab National Bank. This is applicable for year ended 31st March 2023, 31st March 2022 and 31st March 2021. The Company submitted the required information with the bank and the required reconciliation is presented below:

For the period ending March 31st 2023

| Nature of current assets offered as security | Quarter | Amount disclosed as per statement | Amount as per books of accounts | Variance | Remarks |
|----------------------------------------------|---------------|-----------------------------------------|---------------------------------------|----------|--------------------------------------------------------------------------------------------------|
| Inventories and trade receivables | Q1 FY 2022-23 | 1311.45 | 1300.42 | 11.03 | Minor difference while finalization of accounts. |
| Inventories and trade receivables | Q2 FY 2022-23 | 1167.06 | 1126.70 | 40.36 | Stock of otherwise consumable items were included in the stock submitted to bank |
| Inventories and trade receivables | Q3 FY 2022-23 | 1,225.20 | 1,225.20 | - | - |
| Inventories and trade receivables | Q4 FY 2022-23 | 1054.95 | 1208.90 | (153.95) | The statement to bank was submitted with data as at March 28th 2023, and therefore the variance. |

For the period ending March 31st 2022

| Nature of current assets offered as security | Quarter | Amount as per books of accounts | Amount as per books of accounts | Variance | Remarks |
|----------------------------------------------|---------------|---------------------------------|---------------------------------------|----------|---------|
| Inventories and trade receivables | Q1 FY 2021-22 | NA | NA | NA | - |
| Inventories and trade receivables | Q2 FY 2021-22 | NA | NA | NA | - |
| Inventories and trade receivables | Q3 FY 2021-22 | NA | NA | NA | - |
| Inventories and trade receivables | Q4 FY 2021-22 | 964.17 | 964.17 | Nil | - |





Annexure VI Notes to Restated Consolidated Financial Information

For the period ending March 31st 2021

| Nature of current assets offered as security | Quarter | Amount disclosed as per statement | Amount as per books of accounts | Variance | Remarks |
|----------------------------------------------|---------------|-----------------------------------|---------------------------------------|----------|---------|
| Inventories and trade receivables | Q1 FY 2020-21 | NA | NA | NA | - |
| Inventories and trade receivables | Q2 FY 2020-21 | NA | NA | NA | - |
| Inventories and trade receivables | Q3 FY 2020-21 | NA | NA | NA | - |
| Inventories and trade receivables | Q4 FY 2020-21 | NA | NA | NA | - |

48. Other Statutory information

- a) The group does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- b) The group does not have any transactions with companies struck off.
- c) The group does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.
- d) The group has not traded or invested in Crypto currency or Virtual Currency for the year ended March 31, 2023, March 31, 2022 and March 31, 2021.
- e) The group has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the group (Ultimate Beneficiaries); or
 - ii. provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- f) The group has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the group shall:
 - i. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or
 - ii. provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- g) The group has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).





Annexure VI Notes to Restated Consolidated Financial Information

- 49. The parent company had filed Draft Red Herring Prospectus (DRHP) with SEBI on 31st March, 2022 for the fresh issue of capital amounting to Rs. 6,100 Million and Offer for Sale (OFS) of 6,551,690 equity shares. Based on submissions made in the DRHP and other clarifications provided by the company, SEBI has issued The Observation Letter on 02nd August, 2022, enabling the company to proceed further for the issue of fresh capital and OFS. To the extent provided under relevant SEBI regulations the Company has option to change the quantum of fresh issue of capital and/ or the OFS, as the case may.
- 50. Name of the parent company has been changed from Yatharth Hospital & Trauma Care Services Private Limited to Yatharth Hospital & Trauma Care Services Limited during the financial year 2021-22
- 51. The previous year figures have been regrouped /reclassified to confirm with the current year requirements.
- 52. These Restated Consolidated Financial Information were approved by Board in its Meeting held on 05/07/2023 at Noida.

As per our report of even date attached

For R. Nagpal Associates Chartered Accountants

Firm Registration No.: 002626N

opal Ass

New Delh

(Rohit Mehra)

Partner M. No.: 093910

Place: Noida Dated: 05/07/2023 For and on behalf of the Board of Directors Yatharth Hospital & Trauma Care Services Limited

> Dr Ajay Kumar Tyagi Chairman & Whole-Time

Director DIN:01792886

Amit Kumar Singh Chief Executive Officer PAN No.- BFZPS6168A Dr Kapil Kumar Managing Director DIN: 01818736

Pankaj Prabhakar

CFO

PAN No.- AGFPP2937

Ritesh Mishra
CS & Compliance Officer
M. No 51166